• Prognostic and Predictive Biomarkers in Familial Breast Cancer.
    • Deb S, Chakrabarti A, Fox SB.
    • Cancers (Basel). 2023 Feb 20;15(4):1346. doi: 10.3390/cancers15041346.
    • A de novo ERBB3 mutation resulted in Olaparib resistance after successful conversion therapy for a GBC patient bearing BRCA1 mutation.
    • Yang JX, Jia ZY, Liu FT, Wu WG, Li XC, Zou L, Li HF, Zhang F, Bao RF, Peng SY, Lau WY, Liu Y, Li ML, Liu YB.
    • Front Oncol. 2023 Feb 20;13:1078388. doi: 10.3389/fonc.2023.1078388.
    • Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
    • Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, Mahmood RD, Murphy AD, Hasan J, Mitchell CL, Salih Z, Wheeler C, Buckley E, Truelove J, King G, Ainaoui Y, Bhaskar SS, Shaw J, Evans DGR, Kilerci B, Pearce SP, Brady G, Dive C, O'Connor JPB, Wallace AJ, Rothwell DG, Edmondson RJ, Jayson GC.
    • Clin Cancer Res. 2023 Feb 17:CCR-22-3282. doi: 10.1158/1078-0432.CCR-22-3282. Epub ahead of print.

    Related:

    •• Identifier: NCT02855697: Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer (MOLTO). (ClinicalTrials.gov . Accessed 2023 Feb 18.)

    • Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    • Kim J, Jeong K, Jun H, Kim K, Bae JM, Song MG, Yi H, Park S, Woo GU, Lee DW, Kim TY, Lee KH, Im SA.
    • Hum Genomics. 2023 Jan 6;17(1):2. doi: 10.1186/s40246-022-00447-3.
    • Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    • Qi F, Xu Z, Zou Q.
    • Eur Urol. 2023 Jan 3:S0302-2838(22)02873-1. doi: 10.1016/j.eururo.2022.12.024. Epub ahead of print.
    • Letter

    Related:

    •• Original research:

    Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.

    •• Reply:

    Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.

    • Circulating T-cell receptor diversity as predictive biomarker for PARP inhibitors maintenance therapy in high grade serous ovarian cancer.
    • Shu T, Zhou Z, Bai J, Xiao X, Gao M, Zhang N, Wang H, Xia X, Gao Y, Zheng H.
    • Gynecol Oncol. 2023 Jan;168:135-143. doi: 10.1016/j.ygyno.2022.11.013. Epub 2022 Nov 25.
    • Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.
    • Mihajlovich Tsyganov MM, Ibragimova MK, Garbukov EY, Bragina OD, Karchevskaya AA, Usynin EA, Litvyakov NV.
    • Int J Mol Sci. 2022 Dec 22;24(1):207. doi: 10.3390/ijms24010207.
    • Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images.
    • Lazard T, Bataillon G, Naylor P, Popova T, Bidard FC, Stoppa-Lyonnet D, Stern MH, Decencière E, Walter T, Vincent-Salomon A..
    • Cell Rep Med. 2022 Dec 20;3(12):100872. doi: 10.1016/j.xcrm.2022.100872. Epub 2022 Dec 13.

    Related:

    •• Commentary:

    HRD-related morphology discovery in breast cancer by controlling for confounding factors.

    • Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
    • Cristescu R, Liu XQ, Arreaza G, Chen C, Albright A, Qiu P, Marton MJ.
    • BMC Cancer. 2022 Dec 14;22(1):1310. doi: 10.1186/s12885-022-10197-z.
    • BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
    • Darabi S, Braxton DR, Xiu J, Carneiro BA, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry WS, Demeure MJ.
    • Medicina (Kaunas). 2022 Dec 10;58(12):1818. doi: 10.3390/medicina58121818.
    • Details Emerge About Why Cancers Caused by BRCA Mutations Recur.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 16.

    Related:

    •• Original research:

    Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.

    • Study Suggests a PARP Inhibitors Has Wider Cancer Applications.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 9.

    Related:

    •• Original research:

    A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.

    • Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.
    • Shah JB, Pueschl D, Wubbenhorst B, Fan M, Pluta J, D'Andrea K, Hubert AP, Shilan JS, Zhou W, Kraya AA, Llop Guevara A, Ruan C, Serra V, Balmaña J, Feldman M, Morin PJ, Nayak A, Maxwell KN, Domchek SM, Nathanson KL.
    • Nat Commun. 2022 Nov 7;13(1):6728. doi: 10.1038/s41467-022-34523-y.

    Related:

    •• Research news: Details Emerge About Why Cancers Caused by BRCA Mutations Recur. (Inside Precision Medicine)

    • Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study.
    • Garcia-Casado Z, Oaknin A, Mendiola M, Alkorta-Aranburu G, Antunez-Lopez JR, Moreno-Bueno G, Palacios J, Yubero A, Marquez R, Gallego A, Sanchez-Heras AB, Lopez-Guerrero JA, Perez-Segura C, Barretina-Ginesta P, Alarcon J, Gaba L, Marquez A, Matito J, Cueva J, Palacio I, Iglesias M, Arcusa A, Sanchez-Lorenzo L, Guerra-Alia E, Romero I, Vivancos A.
    • J Pers Med. 2022 Nov 4;12(11):1842. doi: 10.3390/jpm12111842.
    • Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    • Musacchio L, Califano D, Bartoletti M, Arenare L, Lorusso D, Losito NS, Cormio G, Greggi S, Raspagliesi F, Valabrega G, Salutari V, Pisano C, Spina A, Russo D, Del Sesto M, Canzonieri V, Ferraù F, Zannoni GF, Loizzi V, Ghizzoni V, Casanova C, Tuninetti V, Ducceschi M, Del Vecchio V, Scalone S, Priolo D, Perrone F, Scambia G, Pignata S.
    • Br J Cancer. 2022 Nov;127(8):1479-1486. doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22.

    Related:

    Identifier: NCT02408536: Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer (MITO 22). (ClinicalTrials.gov)

    • Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    • Chu YY, Yam C, Yamaguchi H, Hung MC.
    • J Biomed Sci. 2022 Oct 25;29(1):86. doi: 10.1186/s12929-022-00870-7.
    • Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    • Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP.
    • J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947. Epub ahead of print.

    Related:

    •• Identifier: NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 19.)

    •• Research news: Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate Cancer. (OncLive)

    • Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
    • Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T, Aoki Y, Sugiyama I, Kawamura M, Yasuda J, Suzuki S, Iwaya T, Saito M, Saito T, Shibata H, Furukawa T, Ishioka C.
    • Cancer Med. 2022 Oct 17. doi: 10.1002/cam4.5349. Epub ahead of print.
    • Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
    • Loehr A, Hussain A, Patnaik A, Bryce AH, Castellano D, Font A, Shapiro J, Zhang J, Sautois B, Vogelzang NJ, Chatta G, Courtney K, Harzstark A, Ricci F, Despain D, Watkins S, King C, Nguyen M, Simmons AD, Chowdhury S, Abida W.
    • Eur Urol. 2022 Oct 12:S0302-2838(22)02639-2. doi: 10.1016/j.eururo.2022.09.010. Epub ahead of print.

    Related:

    •• Commentary:

    BRCA Reversion Mutations in Metastatic Castration-Resistant Prostate Cancer.

    •• Letter:

    Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.

    •• Reply:

    Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.

    • Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing; A Korean Gynecologic Oncology Group study (KGOG 3047).
    • Sa JK, Kim J, Kang S, Kim SW, Song T, Shim SH, Choi MC, No JH, Song JY, Kim D, Kim YM, Kim JH, Lee JW.
    • Int J Cancer. 2022 Oct 1;151(7):1086-1097. doi: 10.1002/ijc.34150. Epub 2022 Jun 27.
    • A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
    • Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML.
    • Nat Cancer. 2022 Oct;3(10):1181-1191. doi: 10.1038/s43018-022-00439-1. Epub 2022 Oct 17.

    Related:

    •• Identifier: NCT02401347: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    •• Identifier: NCT04756765: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    •• Research news: Study Suggests a PARP Inhibitors Has Wider Cancer Applications. (Inside Precision Medicine)

    • Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.
    • Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, Mehine M, Chou J, Capanu M, Mandelker D, Stadler ZK, Birsoy O, Jairam S, Yang C, Li Y, Wong D, Benhamida JK, Ladanyi M, Zhang L, O'Reilly EM.
    • Mol Diagn Ther. 2022 Sep 30. doi: 10.1007/s40291-022-00614-1. Epub ahead of print.
    • What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study.
    • Perrone E, Tudisco R, Pafundi PC, Guido D, Ciucci A, Martinelli E, Zannoni GF, Piermattei A, Spadola S, Ferrante G, Marchetti C, Scambia G, Fagotti A, Gallo D.
    • Cancers (Basel). 2022 Sep 22;14(19):4588. doi: 10.3390/cancers14194588.
    • Corrected Allele Frequency of BRCA1/2 Mutations Is an Independent Prognostic Factor for Treatment Response to PARP-Inhibitors in Ovarian Cancer Patients.
    • Grech CT, Pils D, Aust S, Grimm C, Polterauer S, Reinthaller A, Müllauer L, Reischer T, Bekos C.
    • J Pers Med. 2022 Sep 7;12(9):1467. doi: 10.3390/jpm12091467.
    • Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    • Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Aghajanian C.
    • Gynecol Oncol. 2022 Sep;166(3):425-431. doi: 10.1016/j.ygyno.2022.06.017. Epub 2022 Jul 5.

    Related:

    Identifier: NCT02983799: Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status. (ClinicalTrials.gov)

    • Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology.
    • van der Wiel AMA, Schuitmaker L, Cong Y, Theys J, Van Hoeck A, Vens C, Lambin P, Yaromina A, Dubois LJ.
    • Cancers (Basel). 2022 Aug 27;14(17):4157. doi: 10.3390/cancers14174157.
    • Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data.
    • Blas L, Shiota M, Eto M.
    • Cancers (Basel). 2022 Aug 27;14(17):4161. doi: 10.3390/cancers14174161.
    • Moving the Needle on Precision Medicine in Pancreatic Cancer.
    • O'Kane GM, Lowery MA.
    • J Clin Oncol. 2022 Aug 20;40(24):2693-2705. doi: 10.1200/JCO.21.02514. Epub 2022 Jul 15.
    • Review
    • Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer.
    • Oda K, Aoki D, Tsuda H, Nishihara H, Aoyama H, Inomata H, Shimada M, Enomoto T.
    • Cancer Sci. 2022 Aug 17. doi: 10.1111/cas.15518. Epub ahead of print.
    • Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification.
    • Hollis RL, Meynert AM, Michie CO, Rye T, Churchman M, Hallas-Potts A, Croy I, McCluggage WG, Williams ARW, Bartos C, Iida Y, Okamoto A, Dougherty B, Barrett JC, March R, Matakidou A, Roxburgh P, Semple CA, Harkin DP, Kennedy R, Herrington CS, Gourley C.
    • Clin Cancer Res. 2022 Aug 15;28(16):3546-3556. doi: 10.1158/1078-0432.CCR-22-0368.
    • What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
    • Petrylak DP, Watkins SP, Loehr A.
    • Front Oncol. 2022 Aug 1;12:951348. doi: 10.3389/fonc.2022.951348.
    • A commentary on the discrepancy between blood and tumour BRCA testing: An open question.
    • De Paolis E, Marchetti C, Concolino P, Scambia G, Urbani A, Fagotti A, Minucci A.
    • BJOG. 2022 Aug;129(9):1422-1426. doi: 10.1111/1471-0528.17158. Epub 2022 Apr 5.

    Related:

    Commentary:

    Gene sequencing in ovarian cancer: continually moving targets.

    • Fibroblast testing can inform medical management in individuals with mosaic variants detected on hereditary cancer panels.
    • Sutcliffe EG, Mester JL, Susswein LR, Roberts ME, Marshall ML, Hruska KS.
    • Cancer Genet. 2022 Aug;266-267:86-89. doi: 10.1016/j.cancergen.2022.07.004. Epub 2022 Jul 28.
    • Mutation profiles in circulating cell-free DNA predict acquired resistance to Olaparib in high-grade serous ovarian carcinoma.
    • Hu D, Guo E, Yang B, Qin X, Fu Y, Fan J, Zhuang X, Yao Q, Lu F, Li W, Xiao R, Wu X, Yang X, Wang Z, Liu C, You L, Zang R, Zhou Q, Zhao W, Chen G, Sun C.
    • Cancer Sci. 2022 Aug;113(8):2849-2861. doi: 10.1111/cas.15456. Epub 2022 Jun 26.
    • Views of Israeli healthcare professionals regarding communication of genetic variants of uncertain significance to patients.
    • Levin Fridman A, Raz A, Timmermans S, Shkedi-Rafid S.
    • J Genet Couns. 2022 Aug;31(4):912-921. doi: 10.1002/jgc4.1560. Epub 2022 Feb 4.
    • Practice guidelines for BRCA1/2 tumour testing in ovarian cancer.
    • Grafodatskaya D, O'Rielly DD, Bedard K, Butcher DT, Howlett CJ, Lytwyn A, McCready E, Parboosingh J, Spriggs EL, Vaags AK, Stockley TL.
    • J Med Genet. 2022 Aug;59(8):727-736. doi: 10.1136/jmedgenet-2021-108238. Epub 2022 Apr 7.
    • Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer.
    • Paracchini L, Mannarino L, Beltrame L, Landoni F, Fruscio R, Grassi T, Dalessandro ML, D'Incalci M, Marchini S.
    • Cancers (Basel). 2022 Jul 29;14(15):3697. doi: 10.3390/cancers14153697.
    • Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer.
    • Zografos E, Andrikopoulou A, Papatheodoridi AM, Kaparelou M, Bletsa G, Liontos M, Dimopoulos MA, Zagouri F.
    • Genes (Basel). 2022 Jul 29;13(8):1362. doi: 10.3390/genes13081362.
    • Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
    • Nag S, Aggarwal S, Rauthan A, Warrier N.
    • J Ovarian Res. 2022 Jul 28;15(1):88. doi: 10.1186/s13048-022-01020-1.
    • CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    • You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM.
    • J Clin Oncol. 2022 Jul 22:JCO2200430. doi: 10.1200/JCO.22.00430. Epub ahead of print.
    • Comprehensive Genomic Profiling in the Management of Ovarian Cancer-National Results from Croatia.
    • Cerina D, Matkovic V, Katic K, Belac Lovasic I, Šeparovic R, Canjko I, Bajic Ž, Vrdoljak E.
    • J Pers Med. 2022 Jul 19;12(7):1176. doi: 10.3390/jpm12071176.
    • Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jul 13.
    • Research news

    Related:

    Original research:

    PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.

    • Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer.
    • Moore G, Majumdar R, Powell SN, Khan AJ, Weinhold N, Yin S, Higginson DS.
    • Mol Cancer Res. 2022 Jul 6;20(7):1061-1070. doi: 10.1158/1541-7786.MCR-21-1012.
    • Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
    • Lee JY, Kim BG, Kim JW, Lee JB, Park E, Joung JG, Kim S, Choi CH, Kim HS; Korean Gynecologic Oncology Group (KGOG) investigators.
    • J Gynecol Oncol. 2022 Jul;33(4):e45. doi: 10.3802/jgo.2022.33.e45. Epub 2022 Mar 4.

    Related:

    Identifier: NCT03699449: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION). (ClinicalTrials.gov)

    Commentary:

    A step towards the ambition of precision oncology in recurrent ovarian cancer.

    • Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation.
    • Zarbiv Y, Wygoda YB, Grinshpun A, Hamburger T, Sella T, Breuer S, Maimon O, Rottenberg Y, Peretz T, Kadouri L.
    • Oncol Ther. 2022 Jun 25. doi: 10.1007/s40487-022-00202-7. Epub ahead of print.
    • Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    • Darbeheshti F, Kadkhoda S, Keshavarz-Fathi M, Razi S, Bahramy A, Mansoori Y, Rezaei N.
    • BMC Cancer. 2022 Jun 17;22(1):668. doi: 10.1186/s12885-022-09761-4.
    • A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
    • Tinker AV, Altman AD, Bernardini MQ, Ghatage P, Gien LT, Provencher D, Salvador S, Doucette S, Oza AM.
    • Curr Oncol. 2022 Jun 17;29(6):4354-4369. doi: 10.3390/curroncol29060348.
    • Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
    • Dehdashti F, Reimers MA, Shoghi KI, Chen DL, Luo J, Rogers B, Pachynski RK, Sreekumar S, Weimholt C, Zhou D.
    • Mol Imaging Biol. 2022 Jun 14. doi: 10.1007/s11307-022-01746-w. Epub ahead of print.
    • Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).
    • Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL, Kirchner M, Goldschmid H, Pfarr N, Weichert W, Hübschmann D, Fröhling S, Sutter C, Schaaf CP, Schirmacher P, Endris V, Stenzinger A, Budczies J.
    • NPJ Precis Oncol. 2022 Jun 9;6(1):36. doi: 10.1038/s41698-022-00276-6.
    • Yondelis Fails to Improve Survival in BRCA1/2-Mutant Ovarian Cancer in Phase III ASCO Study.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jun 9.

    Related:

    Identifier: NCT02903004: Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (MITO23). (ClinicalTrials.gov)

    • Leptomeningeal disease in BRIP1-mutated pancreatic adenocarcinoma.
    • Yim E, Leung D.
    • BMJ Case Rep. 2022 Jun 8;15(6):e249837. doi: 10.1136/bcr-2022-249837.
    • Case report
    • Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
    • Saito A, Tanioka M, Hirata M, Watanabe T, Odaka Y, Shimoi T, Sudo K, Noguchi E, Ishikawa M, Yonemori K.
    • Cancer Treat Res Commun. 2022 [Epub 2022 Jun 8];32:100587. doi: 10.1016/j.ctarc.2022.100587. Epub 2022 Jun 8.
    • Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    • Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, Chittenden A, Kane S, Stokes S, Hughes ME, Kim JS, Umeton R, Awad MM, Konstantinopoulos PA, Yurgelun MB, Wolpin BM, Taplin ME, Newmark RE, Johnson BE, Lindeman NI, MacConaill LE, Garber JE, Lin NU.
    • Clin Cancer Res. 2022 Jun 1;28(11):2349-2360. doi: 10.1158/1078-0432.CCR-21-2861.
    • Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.
    • Vergote I, Denys H, Altintas S, Kerger J, Baurain JF, Bours V, Henry S, Van de Vijver K, Lambrechts D, Gennigens C.
    • Facts Views Vis Obgyn. 2022 Jun;14(2):111-120. doi: 10.52054/FVVO.14.2.024.
    • PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
    • Sokol ES, Jin DX, Fine A, Trabucco SE, Maund S, Frampton G, Molinero L, Antonarakis ES.
    • JCO Precis Oncol. 2022 Jun;6:e2100531. doi: 10.1200/PO.21.00531.

    Related:

    Research news: Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients. (Precision Oncology News)

    • Concurrent Germline BRCA1/2 and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options.
    • Ozer M, Ranganathan M, Lecomte N, Schvartzman JM, Walch HS, Chatila WK, Hong J, Carlo MI, Walsh MF, Sheehan M, Mandelker D, Ceyhan-Birsoy O, Maio A, Kemel Y, Iacobuzio-Donahue CA, O'Reilly EM, Yu KH.
    • JCO Precis Oncol. 2022 Jun;6:e2100560. doi: 10.1200/PO.21.00560.
    • Case report
    • Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?
    • Keane F, Park W, O'Reilly EM.
    • JCO Precis Oncol. 2022 Jun;6:e2200141. doi: 10.1200/PO.22.00141.

    Related:

    Letter, Reply:

    Reply to F. Keane et al.

    Original research:

    Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.

    • Evolution in adjuvant treatment of ovarian carcinoma [Évolution des traitements adjuvants des cancers de l'ovaire].
    • Pautier P.
    • Rev Prat. 2022 Jun;72(6):633-637. French.
    • Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    • Rabban JT, Chen LM, Devine WP.
    • Surg Pathol Clin. 2022 Jun;15(2):219-234. doi: 10.1016/j.path.2022.02.003. Epub 2022 May 18.
    • Review
    • Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    • Leibowitz BD, Dougherty BV, Bell JSK, Kapilivsky J, Michuda J, Sedgewick AJ, Munson WA, Chandra TA, Dry JR, Beaubier N, Igartua C, Taxter T.
    • BMC Cancer. 2022 May 28;22(1):587. doi: 10.1186/s12885-022-09669-z.
    • Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay.
    • Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, Leone G, Xiang JZ, Wingate A, Tagawa S, Jayaram A, Linch M; PEACE Consortium, Jamal-Hanjani M, Swanton C, Rubin MA, Wyatt AW, Beltran H, Attard G, Demichelis F.
    • NAR Cancer. 2022 May 27;4(2):zcac016. doi: 10.1093/narcan/zcac016.
    • Case Report: Male Lobular Breast Cancer in Hereditary Cancer Syndromes.
    • Carnevali I, Tedaldi G, Pensotti V, Sahnane N, Micello D, Rovera F, Sessa F, Tibiletti MG.
    • Front Oncol. 2022 May 24;12:891426. doi: 10.3389/fonc.2022.891426.
    • Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin.
    • Berthelet J, Foroutan M, Bhuva DD, Whitfield HJ, El-Saafin F, Cursons J, Serrano A, Merdas M, Lim E, Charafe-Jauffret E, Ginestier C, Ernst M, Hollande F, Anderson RL, Pal B, Yeo B, Davis MJ, Merino D.
    • Cancers (Basel). 2022 May 13;14(10):2404. doi: 10.3390/cancers14102404.
    • Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.
    • Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JT.
    • NPJ Breast Cancer. 2022 May 10;8(1):64. doi: 10.1038/s41523-022-00427-9.
    • BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score.
    • Ergasti R, Marchetti C, Tudisco R, Iervolino A, Naldini A, Oliva R, Inzani F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 May 3;32(5):639-645. doi: 10.1136/ijgc-2021-003116.
    • Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    • Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, Kaneyasu T, Mori S, Mandai M, Matsumura N.
    • JCO Precis Oncol. 2022 May;6:e2200085. doi: 10.1200/PO.22.00085.
    • Survival Benefit of Pembrolizumab for Patients With Pancreatic Adenocarcinoma: A Case Series.
    • Zhao L, Singh V, Ricca A, Lee P.
    • J Med Cases. 2022 May;13(5):240-243. doi: 10.14740/jmc3918. Epub 2022 May 7.
    • Improving ovarian cancer treatment decision using a novel risk predictive tool.
    • Xu Z, Song J, Cao L, Rong Z, Zhang W, He J, Li K, Hou Y.
    • Aging (Albany NY). 2022 Apr 19;14(8):3464-3483. doi: 10.18632/aging.204023. Epub 2022 Apr 19.
    • Prediction of breast cancer risk based on flow variant analysis of circulating peripheral blood mononuclear cells.
    • Loke J, Alim I, Yam S, Klugman S, Xia LC, Gruber D, Tegay D, LaBella A, Onel K, Ostrer H.
    • HGG Adv. 2022 Jan 8 [eCollection 2022 Apr 14];3(2):100085. doi: 10.1016/j.xhgg.2022.100085.
    • Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.
    • Weber-Lassalle K, Ernst C, Reuss A, Möllenhoff K, Baumann K, Jackisch C, Hauke J, Dietrich D, Borde J, Park-Simon TW, Hanker L, Prieske K, Schmidt S, Weber-Lassalle N, Pohl-Rescigno E, Kommoss S, Marmé F, Heitz F, Stingl JC, Schmutzler RK, Harter P, Hahnen E.
    • J Natl Cancer Inst. 2022 Apr 11;114(4):565-570. doi: 10.1093/jnci/djab231.

    Related:

    Commentary:

    Untangling the Relationship Between Clonal Hematopoiesis and Ovarian Cancer Therapies.

    • PARP inhibition in breast cancer: progress made and future hopes.
    • Tung N, Garber JE.
    • NPJ Breast Cancer. 2022 Apr 8;8(1):47. doi: 10.1038/s41523-022-00411-3.
    • Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
    • Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roché HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA.
    • Clin Cancer Res. 2022 Apr 1;28(7):1383-1390. doi: 10.1158/1078-0432.CCR-21-2080.
    • Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    • Lee S, Park K, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Ahn HK, Park WY, Im SA, Park YH.
    • Breast. 2022 Apr;62:52-60. doi: 10.1016/j.breast.2022.01.014. Epub 2022 Jan 29.
    • Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.
    • Moore GM, Powell SN, Higginson DS, Khan AJ.
    • Breast Cancer Res Treat. 2022 Apr;192(3):649-653. doi: 10.1007/s10549-022-06529-z. Epub 2022 Jan 29.
    • Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.
    • Iyevleva AG, Aleksakhina SN, Sokolenko AP, Baskina SV, Venina AR, Anisimova EI, Bizin IV, Ivantsov AO, Belysheva YV, Chernyakova AP, Togo AV, Imyanitov EN.
    • Breast Cancer Res Treat. 2022 Apr;192(2):283-291. doi: 10.1007/s10549-022-06517-3. Epub 2022 Jan 12.
    • Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
    • Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, Saad F.
    • Can Urol Assoc J. 2022 Apr;16(4):132-143. doi: 10.5489/cuaj.7621.
    • Myriad Genetics Launches New Comprehensive Suite of Cancer Tests With Research Registry.
    • Ray T.
    • GenomeWeb. Business & Policy. Business News. 2022 Mar 14.
    • News

    Related:

    Press Release: Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care. (Myriad Genetics)

    • New Myriad Product Combines Multiple Cancer Tests.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Mar 14.

    Related:

    Press Release: Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care. (Myriad Genetics)

    • Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.
    • Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S.
    • NPJ Breast Cancer. 2022 Mar 4;8(1):28. doi: 10.1038/s41523-022-00395-0.
    • Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.
    • Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK.
    • Cancer Med. 2022 Mar;11(6):1474-1483. doi: 10.1002/cam4.4566. Epub 2022 Feb 6.
    • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.
    • Quesada S, Fabbro M, Solassol J.
    • Cancers (Basel). 2022 Feb 23;14(5):1132. doi: 10.3390/cancers14051132.
    • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.
    • Quesada S, Fabbro M, Solassol J.
    • Cancers (Basel). 2022 Feb 21;14(4):1098. doi: 10.3390/cancers14041098.
    • Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    • Chai Y, Chen Y, Zhang D, Wei Y, Li Z, Li Q, Xu B.
    • J Pers Med. 2022 Feb 21;12(2):323. doi: 10.3390/jpm12020323.
    • Theranostic Interpolation of Genomic Instability in Breast Cancer.
    • Rasool R, Ullah I, Mubeen B, Alshehri S, Imam SS, Ghoneim MM, Alzarea SI, Al-Abbasi FA, Murtaza BN, Kazmi I, Nadeem MS.
    • Int J Mol Sci. 2022 Feb 7;23(3):1861. doi: 10.3390/ijms23031861.
    • The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
    • Frugtniet B, Morgan S, Murray A, Palmer-Smith S, White R, Jones R, Hanna L, Fuller C, Hudson E, Mullard A, Quinton AE.
    • BJOG. 2022 Feb;129(3):433-442. doi: 10.1111/1471-0528.16975. Epub 2021 Nov 8.

    Related:

    Commentary:

    Gene sequencing in ovarian cancer: continually moving targets.

    Commentary:

    A commentary on the discrepancy between blood and tumour BRCA testing: An open question.

    • When to use germline genetic testing in prostate cancer.
    • Giri VN.
    • Clin Adv Hematol Oncol. 2022 Feb;20(2):78-81.
    • RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
    • van Wijk LM, Nilas AB, Vrieling H, Vreeswijk MPG.
    • Expert Rev Mol Diagn. 2022 Feb;22(2):185-199. doi: 10.1080/14737159.2022.2020102. Epub 2022 Feb 16.
    • Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    • Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL.
    • Gynecol Oncol. 2022 Feb;164(2):245-253. doi: 10.1016/j.ygyno.2021.12.003. Epub 2021 Dec 11.

    Related:

    Commentary:

    Testing for homologous recombination deficiency - does it provide new insights for the use of veliparib?

    Podcast:

    February 2022 Editor’s Choice: HRD: What does it really mean and are we looking at this the right way?

    • Identifying Transcripts with Tandem Duplications from RNA-Sequencing Data to Predict BRCA1-Type Primary Breast Cancer.
    • Qu S, Martens JWM, Hollestelle A, Smid M.
    • Cancers (Basel). 2022 Jan 31;14(3):753. doi: 10.3390/cancers14030753.
    • Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.
    • Pirš B, Škof E, Smrkolj V, Smrkolj Š.
    • Cancers (Basel). 2022 Jan 27;14(3):631. doi: 10.3390/cancers14030631.
    • Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.
    • Lundy J, McKay O, Croagh D, Ganju V.
    • JCO Precis Oncol. 2022 Jan [27];6:e2100437. doi: 10.1200/PO.21.00437.

    Related:

    Letter, Commentary:

    Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?

    Letter, Reply:

    Reply to F. Keane et al.

    • Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.
    • Cosgrove N, Varešlija D, Keelan S, Elangovan A, Atkinson JM, Cocchiglia S, Bane FT, Singh V, Furney S, Hu C, Carter JM, Hart SN, Yadav S, Goetz MP, Hill ADK, Oesterreich S, Lee AV, Couch FJ, Young LS.
    • Nat Commun. 2022 Jan 26;13(1):514. doi: 10.1038/s41467-022-27987-5.
    • PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers.
    • Collet L, Péron J, Penault-Llorca F, Pujol P, Lopez J, Freyer G, You B.
    • Cancers (Basel). 2022 Jan 25;14(3):599. doi: 10.3390/cancers14030599.
    • What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.
    • Palicelli A, Croci S, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Zanelli M, Chaux A, Cañete-Portillo S, Bonasoni MP, Ascani S, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Gandhi J, Nicoli D, Farnetti E, Piana S, Tafuni A, Bonacini M.
    • Biomedicines. 2022 Jan 22;10(2):236. doi: 10.3390/biomedicines10020236.
    • Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes.
    • Custódio N, Savisaar R, Carvalho C, Bak-Gordon P, Ribeiro MI, Tavares J, Nunes PB, Peixoto A, Pinto C, Escudeiro C, Teixeira MR, Carmo-Fonseca M.
    • Biomedicines. 2022 Jan 18;10(2):199. doi: 10.3390/biomedicines10020199.
    • Computational Prediction of the Pathogenic Status of Cancer-Specific Somatic Variants.
    • Feizi N, Liu Q, Murphy L, Hu P.
    • Front Genet. 2022 Jan 18;12:805656. doi: 10.3389/fgene.2021.805656.
    • Long-term tumour dormancy in a BRCA1 heterozygote.
    • Amuzu S, Fu L, Demko N, Rivera B, Domecq C, de Kock L, Hamel N, Gilbert L, Polak P, Ragoussis J, Foulkes WD.
    • J Med Genet. 2022 Jan 17:jmedgenet-2021-108269. doi: 10.1136/jmedgenet-2021-108269. Epub ahead of print.
    • Case report
    • Value of the loss of heterozygosity to BRCA1 variant classification.
    • Santana Dos Santos E, Spurdle AB, Carraro DM, Briaux A, Southey M, Torrezan G, Petitalot A, Leman R, Lafitte P; kConFab Investigators, Meseure D, Driouch K, Side L, Brewer C, Beck S, Melville A, Callaway A, Revillion F, Folgueira MAAK, Parsons MT, Thorne H, Vincent-Salomon A, Stoppa-Lyonnet D, Bieche I, Caputo SM, Rouleau E.
    • NPJ Breast Cancer. 2022 Jan 17;8(1):9. doi: 10.1038/s41523-021-00361-2.
    • Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation.
    • Wu W, Liu Y, Jin Y, Liu L, Guo Y, Xu M, Hao Q, Li D, Fang W, Zhang A, Zhao P.
    • Front Med (Lausanne). 2022 Jan 13;8:746637. doi: 10.3389/fmed.2021.746637.
    • Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.
    • Liu H, Zhang Z, Chen L, Pang J, Wu H, Liang Z.
    • Front Oncol. 2022 Jan 12;11:798173. doi: 10.3389/fonc.2021.798173.
    • Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    • Zong H, Zhang J, Xu Z, Pan JN, Wang R, Han J, Jiang M, Ren R, Zang L, Wang H, Cao WM.
    • J Cancer. 2022 Jan 9;13(4):1119-1129. doi: 10.7150/jca.65650.
    • Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
    • Ni J, Guo W, Zhao Q, Cheng X, Xu X, Zhou R, Gu H, Chen C, Chen X.
    • Front Oncol. 2022 Jan 6;11:746571. doi: 10.3389/fonc.2021.746571.
    • Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    • Lai Z, Brosnan M, Sokol ES, Xie M, Dry JR, Harrington EA, Barrett JC, Hodgson D.
    • BMC Cancer. 2022 Jan 3;22(1):13. doi: 10.1186/s12885-021-09082-y.
    • Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    • Guffanti F, Alvisi MF, Anastasia A, Ricci F, Chiappa M, Llop-Guevara A, Serra V, Fruscio R, Degasperi A, Nik-Zainal S, Bani MR, Lupia M, Giavazzi R, Rulli E, Damia G.
    • Br J Cancer. 2022 Jan;126(1):120-128. doi: 10.1038/s41416-021-01609-1. Epub 2021 Nov 3.
    • Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
    • De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS.
    • JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789.
    • Race-Specific Genetic Profiles of Homologous Recombination Deficiency in Multiple Cancers.
    • Hsiao YW, Lu TP.
    • J Pers Med. 2021 Dec 3;11(12):1287. doi: 10.3390/jpm11121287.
    • PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.
    • Fuentes-Antrás J, Cescon DW.
    • Ann Oncol. 2021 Dec;32(12):1460-1462. doi: 10.1016/j.annonc.2021.10.005. Epub 2021 Oct 19.
    • Commentary
    • Prognostic difficulties of men with breast cancer.
    • Fentiman IS.
    • Breast J. 2021 Dec;27(12):877-882. doi: 10.1111/tbj.14297. Epub 2021 Oct 15.
    • Review
    • Diagnostic histologique et moléculaire des cancers de l'ovaire - recommandations pour la pratique clinique Saint-Paul 2021: Histological and molecular diagnosis of ovarian.
    • Genestie C, Gladieff L, Frère-Belda ML, Lortholary A, Vaur D, Treilleux I, Lyonnet DS.
    • Bull Cancer. 2021 Dec;108(9S1):S33-S38. doi: 10.1016/S0007-4551(21)00585-3.
    • Guideline
    • Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
    • Paik ES, Heo EJ, Choi CH, Kim JH, Kim JW, Kim YM, Park SY, Lee JW, Kim JW, Kim BG.
    • Cancer Sci. 2021 Dec;112(12):5055-5067. doi: 10.1111/cas.15166. Epub 2021 Oct 25.
    • Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
    • Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O'Malley DM, Leary A, Welch S, Provencher D, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA.
    • Gynecol Oncol. 2021 Dec;163(3):490-497. doi: 10.1016/j.ygyno.2021.08.030. Epub 2021 Sep 30.
    • Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
    • Azzalini E, Barbazza R, Stanta G, Giorda G, Bortot L, Bartoletti M, Puglisi F, Canzonieri V, Bonin S.
    • Gynecol Oncol. 2021 Dec;163(3):498-505. doi: 10.1016/j.ygyno.2021.09.012. Epub 2021 Oct 1.
    • Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    • Hodgson DR, Brown JS, Dearden SP, Lai Z, Elks CE, Milenkova T, Dougherty BA, Lanchbury JS, Perry M, Timms KM, Harrington EA, Barrett JC, Leary A, Pujade-Lauraine E.
    • Gynecol Oncol. 2021 Dec;163(3):563-568. doi: 10.1016/j.ygyno.2021.10.002. Epub 2021 Nov 4.
    • BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer.
    • Elazezy M, Prieske K, Kluwe L, Oliveira-Ferrer L, Peine S, Müller V, Woelber L, Schmalfeldt B, Pantel K, Joosse SA.
    • Mol Oncol. 2021 Dec;15(12):3615-3625. doi: 10.1002/1878-0261.13108. Epub 2021 Oct 12.
    • Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
    • Xu Q, Li Z.
    • Front Pharmacol. 2021 Nov 29;12:743073. doi: 10.3389/fphar.2021.743073.
    • BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report.
    • Pepe F, Pisapia P, Russo G, Nacchio M, Pallante P, Vigliar E, De Angelis C, Insabato L, Bellevicine C, De Placido S, Troncone G, Malapelle U.
    • Genes (Basel). 2021 Nov 28;12(12):1917. doi: 10.3390/genes12121917.
    • GSA: an independent development algorithm for calling copy number and detecting homologous recombination deficiency (HRD) from target capture sequencing.
    • Chen D, Shao M, Meng P, Wang C, Li Q, Cai Y, Song C, Wang X, Shi T.
    • BMC Bioinformatics. 2021 Nov 23;22(1):562. doi: 10.1186/s12859-021-04487-9.
    • Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies.
    • Paracchini L, Mannarino L, Craparotta I, Romualdi C, Fruscio R, Grassi T, Fotia V, Caratti G, Perego P, Calura E, Clivio L, D'Incalci M, Beltrame L, Marchini S.
    • Oncotarget. 2016 Jul 9;12(24):2404-2417. doi: 10.18632/oncotarget.10505. eCollection 2021 Nov 23.
    • Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer.
    • Su R, Liu Y, Wu X, Xiang J, Xi X.
    • Front Mol Biosci. 2021 Nov 19;8:762741. doi: 10.3389/fmolb.2021.762741.
    • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.
    • Zhang M, Ma SC, Tan JL, Wang J, Bai X, Dong ZY, Zhang QX.
    • Front Oncol. 2021 Dec 16;11:772604. doi: 10.3389/fonc.2021.772604.
    • Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
    • Willis SE, Winkler C, Roudier MP, Baird T, Marco-Casanova P, Jones EV, Rowe P, Rodriguez-Canales J, Angell HK, Ng FSL, Waring PM, Hodgson D, Ledermann JA, Weberpals JI, Dean E, Harrington EA, Barrett JC, Pierce AJ, Leo E, Jones GN.
    • Br J Cancer. 2021 Dec;125(12):1666-1676. doi: 10.1038/s41416-021-01560-1. Epub 2021 Oct 18.
    • Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
    • Aldea M, Lam L, Orillard E, Llacer Perez C, Saint-Ghislain M, Gravis G, Fléchon A, Roubaud G, Barthelemy P, Ricci F, Priou F, Neviere Z, Beaufils M, Laguerre B, Hardy AC, Helissey C, Ratta R, Borchiellini D, Pobel C, Joly F, Castro E, Thiery-Vuillemin A, Baciarello G, Fizazi K.
    • Eur J Cancer. 2021 Dec;159:87-97. doi: 10.1016/j.ejca.2021.09.029. Epub 2021 Nov 2.
    • Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
    • Lieb V, Abdulrahman A, Weigelt K, Hauch S, Gombert M, Guzman J, Bellut L, Goebell PJ, Stöhr R, Hartmann A, Wullich B, Taubert H, Wach S.
    • Cells. 2021 Nov 18;10(11):3223. doi: 10.3390/cells10113223.
    • Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing.
    • Jalloul N, Gomy I, Stokes S, Gusev A, Johnson BE, Lindeman NI, Macconaill L, Ganesan S, Garber JE, Khiabanian H.
    • JCO Precis Oncol. 2021 Nov 17;5:PO.21.00279. doi: 10.1200/PO.21.00279.

    Related:

    Letter, Commentary:

    Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing-A Quality Assurance Strategy.

    Letter, Reply:

    Reply to T. Ménard.

    • Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer.
    • McNevin CS, Cadoo K, Baird AM, Murchan P, Sheils O, McDermott R, Finn S.
    • Cancers (Basel). 2021 Nov 14;13(22):5697. doi: 10.3390/cancers13225697.
    • Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes.
    • Billaud A, Chevalier LM, Augereau P, Frenel JS, Passot C, Campone M, Morel A.
    • Genome Med. 2021 Nov 9;13(1):174. doi: 10.1186/s13073-021-00976-x.
    • Examining the Prevalence of Homologous Recombination Repair Defects in ER+ Breast Cancers.
    • Moore GM, Powell SN, Higginson DS, Khan AJ.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S35-S36. doi: 10.1016/j.ijrobp.2021.07.106.
    • Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    • Moore KN, Pothuri B.
    • Cancer J. 2021 Nov-Dec 01;27(6):432-440. doi: 10.1097/PPO.0000000000000558.
    • Review
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.
    • Satyananda V, Oshi M, Endo I, Takabe K.
    • Ann Surg Oncol. 2021 Nov;28(12):7356-7365. doi: 10.1245/s10434-021-10063-5. Epub 2021 May 8.

    Related:

    Commentary:

    ASO Author Reflections: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.

    Commentary:

    ASO Visual Abstract: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.

    • Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
    • Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS.
    • Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27.
    • The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.
    • You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson RT, Pignata S, Pujade-Lauraine E.
    • Cancer Treat Rev. 2021 Nov;100:102294. doi: 10.1016/j.ctrv.2021.102294. Epub 2021 Sep 15.
    • Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma.
    • Kordes M, Tamborero D, Lagerstedt-Robinson K, Yachnin J, Rosenquist R, Löhr JM, Gustafsson Liljefors M.
    • JCO Precis Oncol. 2021 Nov;5:974-980. doi: 10.1200/PO.21.00024.
    • Homologous recombination proficiency in ovarian and breast cancer patients.
    • Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, Dworkin L, Nemunaitis J.
    • BMC Cancer. 2021 Oct 28;21(1):1154. doi: 10.1186/s12885-021-08863-9.
    • The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    • Tao M, Wu X.
    • J Exp Clin Cancer Res. 2021 Oct 26;40(1):338. doi: 10.1186/s13046-021-02139-7.
    • Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report.
    • McFarland TR, Tandar CE, Agarwal N, Swami U.
    • Cancer Treat Res Commun. 2021;29:100480. doi: 10.1016/j.ctarc.2021.100480. Epub 2021 Oct 20.
    • Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing.
    • Wessman S, Fuentes BB, Törngren T, Kvist A, Kokaraki G, Menkens H, Hjerpe E, Hugo Y, Petta TB, Borg Å, Carlson JW.
    • Cancers (Basel). 2021 Oct 19;13(20):5240. doi: 10.3390/cancers13205240.
    • Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
    • Labrie M, Li A, Creason A, Betts C, Keck J, Johnson B, Sivagnanam S, Boniface C, Ma H, Blucher A, Chang YH, Chin K, Vuky J, Guimaraes AR, Downey M, Lim JY, Gao L, Siex K, Parmar S, Kolodzie A, Spellman PT, Goecks J, Coussens LM, Corless CL, Bergan R, Gray JW, Mills GB, Mitri ZI.
    • NPJ Precis Oncol. 2021 Oct 19;5(1):92. doi: 10.1038/s41698-021-00232-w.
    • Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and BRCA1/2 Mutation-Type-Specific Critical Regulation in Breast Cancer.
    • Li Y, Dong W, Zhang P, Zhang T, Ma L, Qu M, Ma X, Zhou X, He Q.
    • Front Cell Dev Biol. 2021 Oct 18;9:750897. doi: 10.3389/fcell.2021.750897.
    • Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
    • Coulson-Gilmer C, Morgan RD, Nelson L, Barnes BM, Tighe A, Wardenaar R, Spierings DCJ, Schlecht H, Burghel GJ, Foijer F, Desai S, McGrail JC, Taylor SS.
    • J Exp Clin Cancer Res. 2021 Oct 16;40(1):323. doi: 10.1186/s13046-021-02124-0.
    • Prognostic Prediction of BRCA Mutations by 18F-FDG PET/CT SUVmax in Breast Cancer.
    • Özdemir S, Silan F, Akgün MY, Araci N, Çirpan I, Koç Öztürk F, Özdemir Ö.
    • Mol Imaging Radionucl Ther. 2021 Oct 15;30(3):158-168. doi: 10.4274/mirt.galenos.2021.82584.
    • Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
    • Chiang YC, Lin PH, Cheng WF.
    • Front Oncol. 2021 Oct 14;11:675972. doi: 10.3389/fonc.2021.675972.
    • Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation.
    • De Paolis E, Concolino P, Onori ME, Santonocito C, Marchetti C, Fagotti A, Scambia G, Urbani A, Minucci A.
    • Mol Biol Rep. 2021 Oct 13. doi: 10.1007/s11033-021-06812-0. Epub ahead of print.
    • Ovarian Cancer With Breast Metastasis and Two Pathogenic Variants of BRCA1 Gene.
    • Kowsarnia S, Javadi N.
    • Cureus. 2021 Oct 11;13(10):e18691. doi: 10.7759/cureus.18691.
    • Setting a diagnostic benchmark for tumor BRCA testing: Detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue - A pilot study.
    • Valtcheva N, Nguyen-Sträuli BD, Wagner U, Freiberger SN, Varga Z, Britschgi C, Dedes KJ, Rechsteiner MP.
    • Exp Mol Pathol. 2021 Oct 9:104705. doi: 10.1016/j.yexmp.2021.104705. Epub ahead of print.
    • PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer.
    • Hsu WJ, Chen CH, Chang YC, Cheng CH, TsaI YH, Lin CW.
    • J Pers Med. 2021 Oct 8;11(10):1009. doi: 10.3390/jpm11101009.
    • Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation.
    • Meng F, Lu L, Tan Y, Duan Q, Lu H.
    • Front Oncol. 2021 Oct 4;11:757965. doi: 10.3389/fonc.2021.757965.
    • CRISPR screens guide the way for PARP and ATR inhibitors biomarker discovery.
    • Schleicher EM, Moldovan GL.
    • FEBS J. 2021 Oct 3. doi: 10.1111/febs.16217. Epub ahead of print.
    • Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study.
    • Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg C, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W.
    • Clin Cancer Res. 2021 Oct 1:clincanres.2199.2021. doi: 10.1158/1078-0432.CCR-21-2199. Epub ahead of print.
    • Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
    • Zavarikina TM, Khokhlova SV, Tyulyandina AS, Khabas GN, Asaturova AV, Nosova YV, Brenner PK, Kapralova MA, Khodirev DS, Stenina MB.
    • Bull Exp Biol Med. 2021 Oct;171(6):755-759. doi: 10.1007/s10517-021-05310-4. Epub 2021 Oct 28.
    • [The Clinical Utility of Liquid Biopsies as Biomarkers in Metastatic Prostate Cancer].
    • Sumiyoshi T, Akamatsu S.
    • Gan To Kagaku Ryoho. 2021 Oct;48(10):1203-1208. Japanese.
    • Review, [Article in Japanese]
    • Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients.
    • Barbosa A, Pinto P, Peixoto A, Guerra J, Pinheiro M, Santos C, Pinto C, Escudeiro C, Bartosch C, Santos R, Brandão A, Silva J, Teixeira MR.
    • Front Oncol. 2021 Sep 30;11:754094. doi: 10.3389/fonc.2021.754094.
    • miR-522 regulates cell proliferation, migration, invasion capacities and acts as a potential biomarker to predict prognosis in triple-negative breast cancer.
    • Wang W, Zhang W, Wu J, Zhou Z, Ma J.
    • Clin Exp Med. 2021 Sep 14. doi: 10.1007/s10238-021-00757-1. Epub ahead of print.
    • Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    • Hodgson D, Lai Z, Dearden S, Barrett JC, Harrington EA, Timms K, Lanchbury J, Wu W, Allen A, Senkus E, Domchek SM, Robson M.
    • Ann Oncol. 2021 Sep 6:S0923-7534(21)04458-6. doi: 10.1016/j.annonc.2021.08.2154. Epub ahead of print.
    • Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types.
    • van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW.
    • Clin Cancer Res. 2021 Sep 2:clincanres.1104.2021. doi: 10.1158/1078-0432.CCR-21-1104. Epub ahead of print.
    • Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA.
    • Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, Pritchard CC, Montgomery B.
    • JAMA Oncol. 2021 Jun 4 [2021 Sept];7(9):1–5 [1378-1382]. doi: 10.1001/jamaoncol.2021.2350. Epub ahead of print.
    • Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study.
    • Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L, Hammond RFL, Gaba F, Jenkins LA, Ahmed M, Kumar A, Jeyarajah A, Lawrence AC, Brockbank E, Phadnis S, Quigley M, El Khouly F, Wuntakal R, Faruqi A, Trevisan G, Casey L, Burghel GJ, Schlecht H, Bulman M, Smith P, Bowers NL, Legood R, Lockley M, Wallace A, Singh N, Evans DG, Manchanda R.
    • Cancers (Basel). 2021 Aug 27;13(17):4344. doi: 10.3390/cancers13174344.
    • Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families.
    • Matis TS, Zayed N, Labraki B, de Ladurantaye M, Matis TA, Camacho Valenzuela J, Hamel N, Atayan A, Rivera B, Tabach Y, Tonin PN, Orthwein A, Mes-Masson AM, El Haffaf Z, Foulkes WD, Polak P.
    • NPJ Breast Cancer. 2021 Aug 25;7(1):109. doi: 10.1038/s41523-021-00315-8.
    • Thyroid Hormone Receptor Beta as Tumor Suppressor: Untapped Potential in Treatment and Diagnostics in Solid Tumors.
    • Davidson CD, Gillis NE, Carr FE.
    • Cancers (Basel). 2021 Aug 24;13(17):4254. doi: 10.3390/cancers13174254.
    • Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    • Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, Kaneyasu T, Mori S, Mandai M, Matsumura N.
    • JCO Precis Oncol. 2021 Aug 11;5:PO.21.00141. doi: 10.1200/PO.21.00141.
    • Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity.
    • Ketola K, Kaljunen H, Taavitsainen S, Kaarijärvi R, Järvelä E, Rodriguez Martin B, Haase K, Woodcock DJ, Tubio J, Wedge DC, Nykter M, Bova GS.
    • Cancer Res. 2021 Aug 4:canres.0371.2021. doi: 10.1158/0008-5472.CAN-21-0371. Epub ahead of print.
    • Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2021 Aug 3.
    • Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
    • Boilève A, Lavaud P, Caron O.
    • Eur Urol Oncol. 2021 Aug;4(4):674-675. doi: 10.1016/j.euo.2021.06.004. Epub 2021 Jun 19.
    • Letter, Comment

    Related:

    Review:

    Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.

    • Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    • Lin J, Sharaf RN, Saganty R, Ahsan D, Feit J, Khoury A, Bergeron H, Chapman-Davis E, Cantillo E, Holcomb K, Blank SV, Liu Y, Thomas C, Christos PJ, Wright DN, Lipkin S, Offit K, Frey MK.
    • Gynecol Oncol. 2021 Aug;162(2):506-516. doi: 10.1016/j.ygyno.2021.05.011. Epub 2021 May 19.
    • MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells.
    • Zeng X, Jiang S, Ruan S, Guo Z, Guo J, Liu M, Ye C, Dong J.
    • Mol Med Rep. 2021 Aug;24(2):548. doi: 10.3892/mmr.2021.12187. Epub 2021 Jun 3.
    • Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    • Siebert AL, Szymaniak BM, Numan Y, Morgans AK.
    • Urol Clin North Am. 2021 Aug;48(3):365-371. doi: 10.1016/j.ucl.2021.03.006. Epub 2021 Jun 10.
    • Review
    • Oncologists' Perceptions of Tumor Genomic Profiling and the Communication of Test Results and Risks.
    • Hall MJ, D'Avanzo P, Chertock Y, Brajuha J, Bass SB.
    • Public Health Genomics. 2021 Jul 29:1-6. doi: 10.1159/000517486. Epub ahead of print.
    • Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma.
    • Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Eftekhariyan Ghamsari MR, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Cancer Study AO, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL.
    • Cancer Res. 2021 Jul 28:canres.0774.2021. doi: 10.1158/0008-5472.CAN-21-0774. Epub ahead of print.
    • Assistance by Routine CT Features Combined With 3D Texture Analysis in the Diagnosis of BRCA Gene Mutation Status in Advanced Epithelial Ovarian Cancer.
    • Li MR, Liu MZ, Ge YQ, Zhou Y, Wei W.
    • Front Oncol. 2021 Jul 26;11:696780. doi: 10.3389/fonc.2021.696780.
    • Rapid progression of metastatic pancreatic adenocarcinoma during platinum-based therapy in a patient harboring a pathogenic BRCA2 germline variant.
    • Sorscher S, Ramkissoon S.
    • Oncologist. 2021 Jul 26. doi: 10.1002/onco.13912. Epub ahead of print.
    • Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    • Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.
    • Breast Cancer. 2021 Jul 24. doi: 10.1007/s12282-021-01276-3. Epub ahead of print.
    • Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
    • Zhang G, Zhang J, Zhu Y, Liu H, Shi Y, Mi K, Li M, Zhao Q, Huang Z, Huang J.
    • Exp Cell Res. 2021 Jul 21:112742. doi: 10.1016/j.yexcr.2021.112742. Epub ahead of print.
    • Prediction of BRCA Gene Mutation in Breast Cancer Based on Deep Learning and Histopathology Images.
    • Wang X, Zou C, Zhang Y, Li X, Wang C, Ke F, Chen J, Wang W, Wang D, Xu X, Xie L, Zhang Y.
    • Front Genet. 2021 Jul 20;12:661109. doi: 10.3389/fgene.2021.661109.
    • OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.
    • Davey MG, Richard V, Lowery AJ, Kerin MJ.
    • Eur J Cancer. 2021 Jul 17;154:209-216. doi: 10.1016/j.ejca.2021.06.032. Epub ahead of print.
    • Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    • Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL; Gynecologic Cancer Intergroup Meta-Analysis Committee.
    • Cancer. 2021 Jul 15;127(14):2432-2441. doi: 10.1002/cncr.33517. Epub 2021 Mar 19.
    • Meta-Analysis
    • Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework.
    • de Belvis AG, Pellegrino R, Castagna C, Morsella A, Pastorino R, Boccia S.
    • J Pers Med. 2021 Jul 13;11(7):654. doi: 10.3390/jpm11070654.
    • The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
    • Shui L, Li X, Peng Y, Tian J, Li S, He D, Li A, Tian B, Li M, Gao H, An N, Yi C, Cao D.
    • J Transl Med. 2021 Jul 12;19(1):301. doi: 10.1186/s12967-021-02972-6.
    • Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
    • Privé BM, Slootbeek PHJ, Laarhuis BI, Naga SP, van der Doelen MJ, van Kalmthout LWM, de Keizer B, Ezziddin S, Kratochwil C, Morgenstern A, Bruchertseifer F, Ligtenberg MJL, Witjes JA, van Oort IM, Gotthardt M, Heskamp S, Janssen MJR, Gerritsen WR, Nagarajah J, Mehra N.
    • Prostate Cancer Prostatic Dis. 2021 Jul 12. doi: 10.1038/s41391-021-00424-2. Epub ahead of print.
    • Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer.
    • Dameri M, Ferrando L, Cirmena G, Vernieri C, Pruneri G, Ballestrero A, Zoppoli G.
    • Int J Mol Sci. 2021 Jul 1;22(13):7154. doi: 10.3390/ijms22137154.
    • Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
    • Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L.
    • Br J Cancer. 2021 Jul;125(1):7-14. doi: 10.1038/s41416-021-01295-z. Epub 2021 Mar 25.
    • Commentary, Review
    • Precision medicine in breast cancer: From clinical trials to clinical practice.
    • Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, Curigliano G.
    • Cancer Treat Rev. 2021 Jul;98:102223. doi: 10.1016/j.ctrv.2021.102223. Epub 2021 May 12.
    • Review
    • Defizienz der homologen Rekombinationsreparatur als prädiktiver Marker : Grundlagen und Nachweis [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
    • Pfarr N, Merkelbach-Bruse S.
    • Pathologe. 2021 Jul;42(4):391-398. German. doi: 10.1007/s00292-021-00950-9. Epub 2021 Jun 21.
    • Review, Article in German
    • Biomarkers for Homologous Recombination Deficiency in Cancer.
    • Wagener-Ryczek S, Merkelbach-Bruse S, Siemanowski J.
    • J Pers Med. 2021 Jun 28;11(7):612. doi: 10.3390/jpm11070612.
    • Assessing Genetic Variants in Matched Biocompartments From Patients With Serous Ovarian Cancer.
    • Sanders BE, Ku L, Walker P, Bitler BG.
    • Technol Cancer Res Treat. 2021 Jan-Dec [First Published June 25, 2021.];20:15330338211027917. doi: 10.1177/15330338211027917.
    • A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
    • Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ.
    • Clin Cancer Res. 2021 Jun 24:clincanres.0121.2021. doi: 10.1158/1078-0432.CCR-21-0121. Epub ahead of print.
    • Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer.
    • Bekos C, Grimm C, Kranawetter M, Polterauer S, Oberndorfer F, Tan Y, Müllauer L, Singer CF.
    • J Pers Med. 2021 Jun 24;11(7):593. doi: 10.3390/jpm11070593.
    • An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
    • Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R.
    • Cancers (Basel). 2021 Jun 22;13(13):3113. doi: 10.3390/cancers13133113.
    • Comparison of Genetic Profiling between Primary Tumor and Circulating Tumor Cells Captured by Microfluidics in Epithelial Ovarian Cancer: Tumor Heterogeneity or Allele Dropout?
    • Chang TY, Chen SW, Lin WH, Huang CE, Evans MI, Chung IF, Wu JW, Ma GC, Chen M.
    • Diagnostics (Basel). 2021 Jun 16;11(6):1102. doi: 10.3390/diagnostics11061102.
    • A DNA methylation-based liquid biopsy for triple-negative breast cancer.
    • Cristall K, Bidard FC, Pierga JY, Rauh MJ, Popova T, Sebbag C, Lantz O, Stern MH, Mueller CR.
    • NPJ Precis Oncol. 2021 Jun 16;5(1):53. doi: 10.1038/s41698-021-00198-9.
    • The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks.
    • van Wijk LM, Kramer CJH, Vermeulen S, Ter Haar NT, de Jonge MM, Kroep JR, de Kroon CD, Gaarenstroom KN, Vrieling H, Bosse T, Vreeswijk MPG.
    • Cancers (Basel). 2021 Jun 15;13(12):2994. doi: 10.3390/cancers13122994.
    • Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer.
    • Vidula N, Niemierko A, Malvarosa G, Yuen M, Lennerz J, Iafrate AJ, Wander SA, Spring L, Juric D, Isakoff S, Younger J, Moy B, Ellisen LW, Bardia A.
    • Clin Cancer Res. 2021 Jun 15;27(12):3404-3413. doi: 10.1158/1078-0432.CCR-20-3444. Epub 2021 Jan 27.

    Related:

    Commentary:

    Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer.

    • Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
    • Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, T'Kint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ.
    • Prostate Cancer Prostatic Dis. 2021 Jun 9. doi: 10.1038/s41391-021-00397-2. Epub ahead of print.
    • Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
    • Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA.
    • Ann Oncol. 2021 Jun 8:S0923-7534(21)02047-0. doi: 10.1016/j.annonc.2021.06.002. Epub ahead of print.
    • Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    • Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall J, Fowler G, Flohr P, Mehra N, Neeb A, Rekowski J, Eisenberger M, Sartor O, Oudard S, Geffriaud-Ricouard C, Ozatilgan A, Chadjaa M, Macé S, Lord C, Baxter J, Pettitt S, Lambros M, Sharp A, Mateo J, Carreira S, Yuan W, de Bono JS.
    • Eur Urol. 2021 Jun 5:S0302-2838(21)01799-1. doi: 10.1016/j.eururo.2021.05.030. Epub ahead of print.
    • Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
    • Stein MK, Oluoha O, Patel K, VanderWalde A.
    • J Pers Med. 2021 Jun 5;11(6):518. doi: 10.3390/jpm11060518.
    • Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations.
    • Kim KH, Kim HS, Kim SS, Shim HS, Yang AJ, Lee JJB, Yoon HI, Ahn JB, Chang JS.
    • Cancer Res Treat. 2021 Jun 4. doi: 10.4143/crt.2020.1247. Epub ahead of print.
    • Advances in the Treatment of Platinum Resistant Epithelial Ovarian Cancer: an update on standard and experimental therapies.
    • Leung SOA, Konstantinopoulos PA.
    • Expert Opin Investig Drugs. 2021 Jun 4. doi: 10.1080/13543784.2021.1939305. Epub ahead of print.
    • Review
    • Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?
    • Fountzilas E, Kotoula V, Koliou GA, Liontos M, Papadopoulou K, Giannoulatou E, Papanikolaou A, Tikas I, Chrisafi S, Mauri D, Chatzopoulos K, Fostira F, Pectasides D, Oikonomopoulos G, Aivazi D, Andrikopoulou A, Visvikis A, Aravantinos G, Zagouri F, Fountzilas G.
    • Front Oncol. 2021 Jun 1;11:683057. doi: 10.3389/fonc.2021.683057.
    • Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian Cancer.
    • Graf RP, Eskander R, Brueggeman L, Stupack DG.
    • JAMA Netw Open. 2021 Jun 1;4(6):e2114162. doi: 10.1001/jamanetworkopen.2021.14162. Erratum in: JAMA Netw Open. 2021 Aug 2;4(8):e2125709.
    • Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    • Zhang X, Devins K, Ko EM, Reyes MC, Simpkins F, Drapkin R, Schwartz LE, Yoon JY.
    • Gynecol Oncol. 2021 Jun;161(3):762-768. doi: 10.1016/j.ygyno.2021.03.019. Epub 2021 Mar 24.
    • Motivations and barriers to pursue cancer genomic testing: A systematic review.
    • Smith-Uffen M, Bartley N, Davies G, Best M.
    • Patient Educ Couns. 2021 Jun;104(6):1325-1334. doi: 10.1016/j.pec.2020.12.024. Epub 2020 Dec 25.
    • Review
    • Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.
    • Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi AB, Montironi R.
    • Int J Mol Sci. 2021 May 24;22(11):5522. doi: 10.3390/ijms22115522.
    • OHSU to Expand Tumor Board Program After Seeing Benefits in Breast Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2021 May 24.
    • BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
    • Sekine M, Nishino K, Enomoto T.
    • Cancers (Basel). 2021 May 23;13(11):2562. doi: 10.3390/cancers13112562.
    • Perthera, Side-Out Foundation Partner to Advance Precision Oncology in Breast Cancer.
    • [No author given]
    • Precision Oncology News. Cancer Specialties. Breast Cancer. 2021 May 21.
    • A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer.
    • King B, McHugh J, Snape K.
    • Appl Clin Genet. 2021 May 20;14:255-266. doi: 10.2147/TACG.S261737.
    • Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity.
    • Phung TN, Webster TH, Lenkiewicz E, Malasi S, Andreozzi M, McCullough AE, Anderson KS, Pockaj BA, Wilson MA, Barrett MT.
    • Sci Rep. 2021 May 19;11(1):10571. doi: 10.1038/s41598-021-90170-1.
    • Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    • Bertucci F, Gonçalves A, Guille A, Adelaïde J, Garnier S, Carbuccia N, Billon E, Finetti P, Sfumato P, Monneur A, Pécheux C, Khran M, Brunelle S, Mescam L, Thomassin-Piana J, Poizat F, Charafe-Jauffret E, Turrini O, Lambaudie E, Provansal M, Extra JM, Madroszyk A, Gilabert M, Sabatier R, Vicier C, Mamessier E, Chabannon C, Pakradouni J, Viens P, André F, Gravis G, Popovici C, Birnbaum D, Chaffanet M.
    • Genome Med. 2021 May 18;13(1):87. doi: 10.1186/s13073-021-00897-9.
    • A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    • Oshi M, Angarita FA, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K.
    • Cancers (Basel). 2021 May 16;13(10):2401. doi: 10.3390/cancers13102401.
    • Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 May 15;81(10):2774-2787. doi: 10.1158/0008-5472.CAN-20-2912. Epub 2021 Jan 29.
    • The Potential Predictors in Chemotherapy Sensitivity.
    • Kim EK, Shin HC.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:381-389. doi: 10.1007/978-981-32-9620-6_19.
    • Review, eBook chapter
    • Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.
    • Paracchini L, D'Incalci M, Marchini S.
    • Cancers (Basel). 2021 May 14;13(10):2386. doi: 10.3390/cancers13102386.
    • Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
    • Dong B, Fan L, Yang B, Chen W, Li Y, Wu K, Zhang F, Dong H, Cheng H, Pan J, Zhu Y, Chi C, Dong L, Sha J, Li L, Yao X, Xue W.
    • J Natl Compr Canc Netw. 2021 May 14;19(8):905-914. doi: 10.6004/jnccn.2020.7663.
    • The Combination of Single-Cell and Next-Generation Sequencing Can Reveal Mosaicism for BRCA2 Mutations and the Fine Molecular Details of Tumorigenesis.
    • Gráf A, Enyedi MZ, Pintér L, Kriston-Pál É, Jaksa G, Bálind Á, Ezer É, Horváth P, Sükösd F, Kiss E, Haracska L.
    • Cancers (Basel). 2021 May 13;13(10):2354. doi: 10.3390/cancers13102354.
    • Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers.
    • Ahn HS, Ho JY, Yu J, Yeom J, Lee S, Hur SY, Jung Y, Kim K, Choi YJ.
    • Cancers (Basel). 2021 May 11;13(10):2300. doi: 10.3390/cancers13102300.
    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
    • Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors.
    • Zhou Z, Li M.
    • JAMA Netw Open. 2021 May 3;4(5):e217728. doi: 10.1001/jamanetworkopen.2021.7728.
    • [Germline and Somatic Mutations in Archived Breast Cancer Specimens of Different Subtypes].
    • Abramov IS, Korneva YS, Shisterova OA, Ikonnikova AY, Emelyanova MA, Lisitsa TS, Krasnov GS, Nasedkina TV.
    • Mol Biol (Mosk). 2021 May-Jun;55(3):412-421. Russian. doi: 10.31857/S0026898421030022.
    • [Article in Russian]
    • Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    • Weberpals JI, Pugh TJ, Marco-Casanova P, Goss GD, Andrews Wright N, Rath P, Torchia J, Fortuna A, Jones GN, Roudier MP, Bernard L, Lo B, Torti D, Leon A, Marsh K, Hodgson D, Duciaume M, Howat WJ, Lukashchuk N, Lazic SE, Whelan D, Sekhon HS.
    • Cancer Med. 2021 May;10(9):3045-3058. doi: 10.1002/cam4.3831. Epub 2021 Apr 3.
    • Aberrations of DNA repair pathways in prostate cancer: A cornerstone of precision oncology.
    • Boussios S, Rassy E, Shah S, Ioannidou E, Sheriff M, Pavlidis N.
    • Expert Opin Ther Targets. 2021 May;25(5):329-333. doi: 10.1080/14728222.2021.1951226. Epub 2021 Jul 8.
    • Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series.
    • Kasherman L, Garg S, Tchrakian N, Clarke B, Karakasis K, Kim RH, Stockley TL, Dhani N, Oza AM, Lheureux S.
    • Gynecol Oncol Rep. 2021 Feb 12;36:100729. doi: 10.1016/j.gore.2021.100729. eCollection 2021 May.
    • The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology.
    • Nakken S, Lilleby W, Switlyk MD, Knudsen KE, Lilleby O, Zhao S, Kaveh F, Ekstrøm PO, Urbanucci A, Hovig E.
    • J Pers Med. 2021 Apr 22;11(5):330. doi: 10.3390/jpm11050330.
    • Preferences for and acceptability of receiving pharmacogenomic results by mail: A focus group study with a primarily African-American cohort.
    • Chan PA, Lewis KL, Biesecker BB, Erby LH, Fasaye GA, Epps S, Biesecker LG, Turbitt E.
    • J Genet Couns. 2021 Apr 19. doi: 10.1002/jgc4.1424. Epub ahead of print.
    • Age-related activity of Poly (ADP-ribose) polymerase (PARP) in men with localized prostate cancer.
    • Deniz M, Zengerling F, Gundelach T, Moreno-Villanueva M, Bürkle A, Janni W, Bolenz C, Kostezka S, Marienfeld R, Benckendorff J, Friedl TWP, Wiesmüller L, Rall-Scharpf M.
    • Mech Ageing Dev. 2021 Apr 19:111494. doi: 10.1016/j.mad.2021.111494. Epub ahead of print.
    • Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients.
    • Melisi D, Cavaliere A, Gobbo S, Fasoli G, Allegrini V, Simionato F, Gaule M, Casalino S, Pesoni C, Zecchetto C, Merz V, Mambrini A, Barbi E, Girelli R, Giardino A, Frigerio I, Scalamogna R, Avitabile A, Castellani S, Milella M, Butturini G.
    • Pancreatology. 2021 Apr 19:S1424-3903(21)00143-5. doi: 10.1016/j.pan.2021.04.004. Epub ahead of print.
    • Germline and somatic mutation profile in Cancer patients revealed by a medium-sized pan-Cancer panel.
    • Li Z, Wang H, Zhang Z, Meng X, Liu D, Tang Y.
    • Genomics. 2021 Apr 17:S0888-7543(21)00156-7. doi: 10.1016/j.ygeno.2021.04.029. Epub ahead of print.
    • Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.
    • Takahashi K, Takenaka M, Okamoto A, Bowtell DDL, Kohno T.
    • Cancers (Basel). 2021 Apr 7;13(8):1769. doi: 10.3390/cancers13081769.
    • Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
    • Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K.
    • Cancers (Basel). 2021 Apr 1;13(7):1656. doi: 10.3390/cancers13071656.
    • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
    • Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM.
    • JAMA Oncol. 2021 Apr 1;7(4):525-533. doi: 10.1001/jamaoncol.2020.7987.

    Related:

    Editorial:

    Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations.

    Letter, Comment:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Press: Germline Testing: Variant in 1 in 6 Cases of Advanced Cancer. (Medscape Oncology)

    • Incorporating Genomic and Genetic Testing into the Treatment of Metastatic Luminal Breast Cancer.
    • Grill S, Klein E.
    • Breast Care (Basel). 2021 Apr;16(2):101-107. doi: 10.1159/000513800. Epub 2021 Jan 20.
    • Review
    • Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer Overall Survival.
    • Earl J, Barreto E, Castillo ME, Fuentes R, Rodríguez-Garrote M, Ferreiro R, Reguera P, Muñoz G, Garcia-Seisdedos D, López JV, Sainz B Jr, Malats N, Carrato A.
    • Cancers (Basel). 2021 Mar 31;13(7):1612. doi: 10.3390/cancers13071612. Erratum in: Cancers (Basel). 2021 Jul 22;13(15):3687.
    • Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients.
    • Barakeh DH, Aljelaify R, Bashawri Y, Almutairi A, Alqubaishi F, Alnamnakani M, Almubarak L, Al Naeem A, Almushawah F, Alrashed M, Abedalthagafi M.
    • Oncotarget. 2021 Mar 30;12(7):686-697. doi: 10.18632/oncotarget.27909.
    • Intermountain Gets National Stage, Myriad Adds Tumor Profiling Panel With Combined Test Offering.
    • Ray T.
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 24.
    • News
    • Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
    • Naqvi MF, Vo HH, Vining D, Tsimberidou AM.
    • Ther Adv Med Oncol. 2021 Mar 24;13:17588359211001538. doi: 10.1177/17588359211001538.
    • The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study.
    • Toss A, Piombino C, Tenedini E, Bologna A, Gasparini E, Tarantino V, Filieri ME, Cottafavi L, Giovanardi F, Madrigali S, Civallero M, Marcheselli L, Marchi I, Domati F, Venturelli M, Barbieri E, Grandi G, Tagliafico E, Cortesi L.
    • Diagnostics (Basel). 2021 Mar 21;11(3):565. doi: 10.3390/diagnostics11030565.
    • Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
    • Stok C, Kok YP, van den Tempel N, van Vugt MATM.
    • Nucleic Acids Res. 2021 Mar 21:gkab151. doi: 10.1093/nar/gkab151. Epub ahead of print.
    • Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
    • Sharma Saha S, Gentles L, Bradbury A, Brecht D, Robinson R, O'Donnell R, Curtin NJ, Drew Y.
    • Cancers (Basel). 2021 Mar 20;13(6):1420. doi: 10.3390/cancers13061420.
    • The Clinical and Pathological Profile of BRCA1 Gene Methylated Breast Cancer Women: A Meta-Analysis.
    • Ruscito I, Gasparri ML, De Marco MP, Costanzi F, Besharat AR, Papadia A, Kuehn T, Gentilini OD, Bellati F, Caserta D.
    • Cancers (Basel). 2021 Mar 19;13(6):1391. doi: 10.3390/cancers13061391.
    • Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.
    • Ewing A, Meynert A, Churchman M, Grimes G, Hollis RL, Herrington CS, Rye T, Bartos C, Croy I, Ferguson MJ, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, Ennis D, Genomes Partnership TS, McMahon L, Matakidou A, Dougherty BA, March R, Barrett JC, McNeish IA, Biankin AV, Roxburgh P, Gourley C, Semple CA.
    • Clin Cancer Res. 2021 Mar 19:clincanres.CCR-20-4068-A.2020. doi: 10.1158/1078-0432.CCR-20-4068. Epub ahead of print.
    • Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom.
    • Akaev I, Rahimi S, Onifade O, Gardner FJE, Castells-Rufas D, Jones E, Acharige S, Yeoh CC.
    • Diagnostics (Basel). 2021 Mar 19;11(3):547. doi: 10.3390/diagnostics11030547.
    • The Role of Exosomes in Breast Cancer Diagnosis.
    • Piombino C, Mastrolia I, Omarini C, Candini O, Dominici M, Piacentini F, Toss A.
    • Biomedicines. 2021 Mar 18;9(3):312. doi: 10.3390/biomedicines9030312.
    • Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines.
    • Amuzu S, Carmona E, Mes-Masson AM, Greenwood CMT, Tonin PN, Ragoussis J.
    • Cancers (Basel). 2021 Mar 15;13(6):1296. doi: 10.3390/cancers13061296.
    • Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients.
    • Li Y, Zhang X, Gao Y, Shang C, Yu B, Wang T, Su J, Huang C, Wu Y, Guo H, Ha C.
    • Front Oncol. 2021 Mar 5;10:625866. doi: 10.3389/fonc.2020.625866.
    • Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 2.
    • Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities.
    • Lee MS, Pant S.
    • Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-13. doi: 10.1200/EDBK_321255.
    • Germline and tumor BRCA1/2 mutations in Chinese high grade serous ovarian cancer patients.
    • Ji G, Yao Q, Bao L, Zhang J, Bai Q, Zhu X, Tu X, Bi R, Zhou X.
    • Ann Transl Med. 2021 Mar;9(6):453. doi: 10.21037/atm-20-6827.
    • Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients.
    • Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, Wu X.
    • Ann Transl Med. 2021 Mar;9(5):364. doi: 10.21037/atm-20-5136.
    • Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
    • Ghezelayagh TS, Pennington KP, Norquist BM, Khasnavis N, Radke MR, Kilgore MR, Garcia RL, Lee M, Katz R, Leslie KK, Risques RA, Swisher EM.
    • Gynecol Oncol. 2021 Mar;160(3):786-792. doi: 10.1016/j.ygyno.2020.12.007. Epub 2020 Dec 26.
    • Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
    • Yu J, Cho E, Choi J, Lim JE, Lee J, Kang M, Sung HH, Jeong BC, Seo SI, Jeon SS, Lee HM, Jeon HG.
    • Investig Clin Urol. 2021 Mar;62(2):224-232. doi: 10.4111/icu.20200406.
    • Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients.
    • Lu HY, Tai YJ, Chen YL, Chiang YC, Hsu HC, Cheng WF.
    • J Gynecol Oncol. 2021 Mar;32(2):e18. doi: 10.3802/jgo.2021.32.e18. Epub 2020 Dec 3.
    • The BRCA1 c.788G > T (NM_007294.4) variant in a high grade serous ovarian cancer (HGSOC) patient: foods for thought.
    • De Paolis E, Pietragalla A, De Bonis M, Fagotti A, Urbani A, Scambia G, Minucci A.
    • Mol Biol Rep. 2021 Mar;48(3):2985-2992. doi: 10.1007/s11033-021-06243-x. Epub 2021 Mar 3.
    • Case report
    • Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
    • Morizono A, Tanabe M, Ikemura M, Sasaki T, Ushiku T, Seto Y.
    • J Hum Genet. 2021 Feb 27. doi: 10.1038/s10038-021-00911-3. Epub ahead of print.
    • Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
    • Huang CC, Tsai YF, Liu CY, Chao TC, Lien PJ, Lin YS, Feng CJ, Chiu JH, Hsu CY, Tseng LM.
    • BMC Cancer. 2021 Feb 25;21(1):199. doi: 10.1186/s12885-021-07931-4.
    • Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
    • How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS.
    • Cancers (Basel). 2021 Feb 24;13(5):946. doi: 10.3390/cancers13050946.
    • Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
    • Pandya D, Shah M, Kaplan F, Martino C, Levy G, Kazanjian M, Batter S, Martignetti J, Frank RC.
    • Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1):a005801. doi: 10.1101/mcs.a005801.
    • BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis.
    • Salwa A, Ferraresi A, Chinthakindi M, Vallino L, Vidoni C, Dhanasekaran DN, Isidoro C.
    • Biomedicines. 2021 Feb 18;9(2):207. doi: 10.3390/biomedicines9020207.
    • Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
    • Chen MK.
    • FEBS J. 2021 Feb 11. doi: 10.1111/febs.15730. Epub ahead of print.
    • Commentary
    • Molecular analyses of triple-negative breast cancer in the young and elderly.
    • Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Campos AB, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Staaf J.
    • Breast Cancer Res. 2021 Feb 10;23(1):20. doi: 10.1186/s13058-021-01392-0.
    • Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
    • Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons A, Loehr A, Venstrom JM, Oxnard GR.
    • Clin Cancer Res. 2021 Feb 8. doi: 10.1158/1078-0432.CCR-20-4805. Epub ahead of print.

    Related:

    Commentary, Review:

    Liquid Biopsy: It's the Bloody Truth!

    • Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    • Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE.
    • Eur J Cancer. 2021 Feb 9;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub ahead of print.
    • DNA damage response inhibitors: An avenue for TNBC treatment.
    • Jin J, Tao Z, Cao J, Li T, Hu X.
    • Biochim Biophys Acta Rev Cancer. 2021 Feb 5:188521. doi: 10.1016/j.bbcan.2021.188521. Epub ahead of print.
    • Review
    • Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
    • Kikuchi J, Ohhara Y, Takada K, Tanabe H, Hatanaka K, Amano T, C Hatanaka K, Hatanaka Y, Mitamura T, Kato M, Shibata Y, Yabe I, Endoh A, Komatsu Y, Matsuno Y, Sugiyama M, Manabe A, Sakurai A, Takahashi M, Naruse H, Torimoto Y, Dosaka-Akita H, Kinoshita I.
    • Jpn J Clin Oncol. 2021 Feb 3:hyaa277. doi: 10.1093/jjco/hyaa277. Epub ahead of print.
    • Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    • Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, Olmos D.
    • Br J Cancer. 2021 Feb;124(3):552-563. doi: 10.1038/s41416-020-01114-x. Epub 2020 Oct 27.
    • Droplet digital PCR for large genomic rearrangements detection: A promising strategy in tissue BRCA1 testing.
    • De Paolis E, De Bonis M, Concolino P, Piermattei A, Fagotti A, Urbani A, Scambia G, Minucci A, Capoluongo E.
    • Clin Chim Acta. 2021 Feb;513:17-24. doi: 10.1016/j.cca.2020.12.001. Epub 2020 Dec 7.
    • Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells.
    • Färkkilä A, Rodríguez A, Oikkonen J, Gulhan DC, Nguyen H, Domínguez J, Ramos S, Mills CE, Perez-Villatoro F, Lazaro JB, Zhou J, Clairmont CS, Moreau LA, Park PJ, Sorger PK, Hautaniemi S, Frias S, D'Andrea AD.
    • Cancer Res. 2021 Jan 29:canres.2912.2020. doi: 10.1158/0008-5472.CAN-20-2912. Epub ahead of print.
    • Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    • Golan T, O'Kane GM, Denroche RE, Raitses-Gurevich M, Grant RC, Holter S, Wang Y, Zhang A, Jang GH, Stossel C, Atias D, Halperin S, Berger R, Glick Y, Patrick Park JY, Cuggia A, Williamson L, Wong HL, Schaeffer DF, Renouf DJ, Borgida A, Dodd A, Wilson JM, Fischer SE, Notta F, Knox JJ, Zogopoulos G, Gallinger S.
    • Gastroenterology. 2021 Jan 29:S0016-5085(21)00326-7. doi: 10.1053/j.gastro.2021.01.220. Epub ahead of print.
    • CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
    • Heinze K, Rengsberger M, Gajda M, Jansen L, Osmers L, Oliveira-Ferrer L, Schmalfeldt B, Dürst M, Häfner N, Runnebaum IB.
    • Clin Epigenetics. 2021 Jan 22;13(1):15. doi: 10.1186/s13148-021-01006-8.
    • Homologous recombination deficiency: how genomic signatures are generated.
    • Setton J, Reis-Filho JS, Powell SN.
    • Curr Opin Genet Dev. 2021 Jan 18;66:93-100. doi: 10.1016/j.gde.2021.01.002. Epub ahead of print.
    • Review
    • Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    • Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES.
    • Mod Pathol. 2021 Jan 18. doi: 10.1038/s41379-020-00731-4. Epub ahead of print.
    • Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
    • Gogineni V, Morand S, Staats H, Royfman R, Devanaboyina M, Einloth K, Dever D, Stanbery L, Aaron P, Manning L, Walter A, Edelman G, Dworkin L, Nemunaitis J.
    • J Cancer. 2021 Jan 1;12(1):38-53. doi: 10.7150/jca.49406.
    • Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
    • Kurnit KC, Fleming GF, Lengyel E.
    • Obstet Gynecol. 2021 Jan 1;137(1):108-121. doi: 10.1097/AOG.0000000000004173.
    • First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
    • Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS.
    • Cancer Discov. 2021 Jan;11(1):80-91. doi: 10.1158/2159-8290.CD-20-0868. Epub 2020 Sep 28.

    Related:

    Commentary:

    ATR Inhibition as an Attractive Therapeutic Resource against Cancer.

    Press: Bayer's ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest (Precision Oncology News)

    • PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    • Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R.
    • Mol Med Rep. 2021 Jan;23(1):75. doi: 10.3892/mmr.2020.11713. Epub 2020 Nov 25.
    • Case report
    • Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial.
    • Callens C, Vaur D, Soubeyran I, Rouleau E, Just PA, Guillerm E, Golmard L, Goardon N, Sevenet N, Cabaret O, Harter P, Gonzalez-Martin A, Fujiwara K, Cecere SC, Colombo N, Marth C, Vergote I, Maenpaa J, Pujade-Lauraine E, Ray-Coquard I.
    • J Natl Cancer Inst. 2020 Dec 29:djaa193. doi: 10.1093/jnci/djaa193. Epub ahead of print.
    • Non-invasive Technology Advances in Cancer-A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers.
    • Openshaw MR, McVeigh TP.
    • Front Digit Health. 2020 Dec 11;2:573010. doi: 10.3389/fdgth.2020.573010.
    • Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Grandal B, Evrevin C, Laas E, Jardin I, Rozette S, Laot L, Dumas E, Coussy F, Pierga JY, Brain E, Saule C, Stoppa-Lyonnet D, Frank S, Sénéchal C, Lae M, De Croze D, Bataillon G, Guerin J, Reyal F, Hamy AS.
    • Cancers (Basel). 2020 Dec 8;12(12):3681. doi: 10.3390/cancers12123681.
    • Current practices on genetic testing in ovarian cancer.
    • Fostira F, Papadimitriou M, Papadimitriou C.
    • Ann Transl Med. 2020 Dec;8(24):1703. doi: 10.21037/atm-20-1422.
    • Genetic heterogeneity during breast cancer progression in young patients.
    • Hagio K, Hatanaka KC, Amano T, Matsuno Y, Hatanaka Y, Yamashita H.
    • Breast. 2021 Dec;60:206-213. doi: 10.1016/j.breast.2021.10.011. Epub 2021 Oct 28.
    • Biomarkers in Her2- Positive Disease.
    • Klocker EV, Suppan C.
    • Breast Care (Basel). 2020 Dec;15(6):586-593. doi: 10.1159/000512283. Epub 2020 Oct 28.
    • PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
    • VanderWeele DJ, Hussain M.
    • Clin Adv Hematol Oncol. 2020 Dec;18(12):808-815.
    • Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    • Jang A, Sartor O, Barata PC, Paller CJ.
    • Cancers (Basel). 2020 Nov 21;12(11):3467. doi: 10.3390/cancers12113467.
    • Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
    • Turashvili G, Lazaro C, Ying S, Charames G, Wong A, Hamilton K, Yee D, Agro E, Chang M, Pollett A, Lerner-Ellis J.
    • Cancers (Basel). 2020 Nov 21;12(11):3468. doi: 10.3390/cancers12113468.
    • Beware Liquid Biopsies to Guide PARP Blockade.
    • [No author given]
    • Cancer Discov. 2020 Nov 18. doi: 10.1158/2159-8290.CD-NB2020-105. Epub ahead of print.
    • Research news
    • Triple-negative breast cancer: promising prognostic biomarkers currently in development.
    • Sukumar J, Gast K, Quiroga D, Lustberg M, Williams N.
    • Expert Rev Anticancer Ther. 2020 Nov 16. doi: 10.1080/14737140.2021.1840984. Epub ahead of print.
    • Review
    • Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China.
    • [No author given]
    • Precision Oncology News. 2020 Nov 16.
    • Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review.
    • Nagaraj G, Ma CX.
    • Adv Ther. 2020 Nov 15. doi: 10.1007/s12325-020-01552-2. Epub ahead of print.
    • Pan-cancer landscape of homologous recombination deficiency.
    • Nguyen L, W M Martens J, Van Hoeck A, Cuppen E.
    • Nat Commun. 2020 Nov 4;11(1):5584. doi: 10.1038/s41467-020-19406-4.
    • Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
    • Gachechiladze M, Skarda J, Bouchalova K, Soltermann A, Joerger M.
    • Front Oncol. 2020 Nov 3;10:581217. doi: 10.3389/fonc.2020.581217.
    • Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer.
    • Huang X, Shao D, Wu H, Zhu C, Guo D, Zhou Y, Chen C, Lin Y, Lu T, Zhao B, Wang C, Sun Q.
    • Front Oncol. 2020 Oct 30;10:583314. doi: 10.3389/fonc.2020.583314. PMID: 33194720; PMCID: PMC7662137.
    • Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
    • Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, Shiraishi Y, Chiba K, Kataoka Y, Torii M, Yoshibayashi H, Yamagami K, Okamura R, Moriguchi Y, Kato H, Tsuyuki S, Yamauchi A, Suwa H, Inamoto T, Miyano S, Ogawa S, Toi M.
    • Commun Biol. 2020 Oct 16;3(1):578. doi: 10.1038/s42003-020-01301-9.
    • Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case.
    • Izawa M, Kosaka T, Nakamura K, Oba J, Hishida T, Hongo H, Mikami S, Nishihara H, Oya M.
    • IJU Case Rep. 2020 Oct 15;4(1):14-17. doi: 10.1002/iju5.12224.
    • Using Co-segregation and Loss of Heterozygosity Analysis to Define the Pathogenicity of Unclassified Variants in Hereditary Breast Cancer Patients.
    • Grasel RS, Felicio PS, de Paula AE, Campacci N, Garcia FAO, de Andrade ES, Evangelista AF, Fernandes GC, Sabato CDS, De Marchi P, Souza CP, de Paula CAA, Torrezan GT, Galvão HCR, Carraro DM, Palmero EI.
    • Front Oncol. 2020 Oct 2;10:571330. doi: 10.3389/fonc.2020.571330.
    • Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology.
    • Dixon K, Young S, Shen Y, Thibodeau ML, Fok A, Pleasance E, Zhao E, Jones M, Aubert G, Armstrong L, Virani A, Regier D, Gelmon K, Renouf D, Chia S, Bosdet I, Rassekh SR, Deyell RJ, Yip S, Fisic A, Titmuss E, Abadi S, Jones SJM, Sun S, Karsan A, Marra M, Laskin J, Lim H, Schrader KA.
    • JNCI Cancer Spectr. 2020 May 29 [eCollection 2020 Oct];4(5):pkaa045. doi: 10.1093/jncics/pkaa045.
    • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    • Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR.
    • Ann Oncol. 2020 Sep 28:S0923-7534(20)42164-7. doi: 10.1016/j.annonc.2020.08.2102. Epub ahead of print.
    • A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy.
    • Pan Y, Jia LP, Liu Y, Han Y, Li Q, Zou Q, Zhang Z, Huang J, Deng Q.
    • J Ovarian Res. 2020 Sep 19;13(1):112. doi: 10.1186/s13048-020-00712-w.
    • Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
    • Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Katz SJ.
    • JNCI Cancer Spectr. 2020 Sep 18;5(1):pkaa083. doi: 10.1093/jncics/pkaa083.
    • What is the role of PARP inhibitors in pancreatic cancer?
    • Halder R, T Shroff R.
    • Expert Rev Anticancer Ther. 2020 Sep 11:1-6. doi: 10.1080/14737140.2020.1816174. Epub ahead of print.
    • Implementing NGS-based BRCA tumour tissue testing in FFPE ovarian carcinoma specimens: hints from a real-life experience within the framework of expert recommendations.
    • Rivera D, Paudice M, Gismondi V, Anselmi G, Vellone VG, Varesco L; Ligurian BRCA Working Group.
    • J Clin Pathol. 2020 Sep 7:jclinpath-2020-206840. doi: 10.1136/jclinpath-2020-206840. Epub ahead of print.
    • FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.
    • Kimura R, Ohtsuka T, Kubo M, Kajihara A, Fujii A, Watanabe Y, Mori Y, Ikenaga N, Nakata K, Shindo K, Ohuchida K, Nakamura M.
    • Surg Today. 2020 Sep 4. doi: 10.1007/s00595-020-02123-2. Epub ahead of print.
    • Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.
    • Yadav G, Vashisht M, Yadav V, Shyam R.
    • Int J Prev Med. 2020 Sep 3;11:135. doi: 10.4103/ijpvm.IJPVM_75_19.
    • Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    • Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Ferguson NL, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen MB, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom PJ, Alexander B, Brown C, Pusztai L, Ross JS, Ramkissoon SH.
    • Oncologist. 2020 Sep 1. doi: 10.1634/theoncologist.2020-0449. Epub ahead of print.
    • Moving Beyond BRCA - Incorporating Molecular Assays into Ovarian Cancer trials.
    • McMullen M, Karakasis K, Oza AM.
    • Clin Cancer Res. 2020 Aug 14. doi: 10.1158/1078-0432.CCR-20-2429. Epub ahead of print.
    • News
    • Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection.
    • Paradiso AV, Patruno M, Digennaro M, Tommasi S, Pilato B, Argentiero A, Brunetti O, Silvestris N.
    • Front Oncol. 2020 Aug 12;10:1292. doi: 10.3389/fonc.2020.01292.
    • BRCA sequencing of tumors: understanding its implications in the oncology community.
    • Wong RSJ, Lee SC.
    • Chin Clin Oncol. 2020 Aug 10:cco-19-198. doi: 10.21037/cco-19-198. Epub ahead of print.
    • Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
    • Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M, Akahane T, Kameyama K, Yamagami W, Kataoka F, Aoki D.
    • Sci Rep. 2020 Jul 28;10(1):12581. doi: 10.1038/s41598-020-69488-9.
    • Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
    • Min A, Kim K, Jeong K, Choi S, Kim S, Suh KJ, Lee KH, Kim S, Im SA.
    • Sci Rep. 2020 Jul 27;10(1):12506. doi: 10.1038/s41598-020-68176-y.
    • BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    • Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM.
    • Breast Cancer Res. 2020 Jul 25;22(1):79. doi: 10.1186/s13058-020-01313-7.
    • PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
    • Lee EK, Matulonis UA.
    • Cancers (Basel). 2020 Jul 25;12(8):2054. doi: 10.3390/cancers12082054.
    • Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients.
    • Horiuchi Y, Matsubayashi H, Kiyozumi Y, Nishimura S, Higashigawa S, Kado N, Nagashima T, Mizuguchi M, Ohnami S, Arai M, Urakami K, Kusuhara M, Yamaguchi K.
    • Hum Genet. 2020 Jul 24. doi: 10.1007/s00439-020-02207-6. Epub ahead of print.
    • Clinical implications of breast cancer tumor genomic testing.
    • Damodaran S, Sember QC, Arun BK.
    • Breast J. 2020 Jul 22. doi: 10.1111/tbj.13966. Epub ahead of print.
    • Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance.
    • Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ, Lord CJ.
    • Cancer Discov. 2020 Jul 22:CD-19-1485. doi: 10.1158/2159-8290.CD-19-1485. Epub ahead of print.
    • Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer.
    • Park S, Lee E, Park S, Lee S, Nam SJ, Kim SW, Lee JE, Yu JH, Kim JY, Ahn JS, Im YH, Park WY, Park K, Park YH.
    • Mol Cancer Res. 2020 Jun 17:molcanres.1108.2019. doi: 10.1158/1541-7786.MCR-19-1108. Epub ahead of print.
    • Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
    • Marchetti C, Minucci A, D'Indinosante M, Ergasti R, Arcieri M, Capoluongo ED, Pietragalla A, Caricato C, Scambia G, Fagotti A.
    • Gynecol Oncol. 2020 Jun 15:S0090-8258(20)32294-0. doi: 10.1016/j.ygyno.2020.06.479. Epub ahead of print.
    • Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
    • Watanabe T, Honda T, Totsuka H, Yoshida M, Tanioka M, Shiraishi K, Shimada Y, Arai E, Ushiama M, Tamura K, Yoshida T, Kanai Y, Kohno T.
    • Breast Cancer Res Treat. 2020 Jun 3. doi: 10.1007/s10549-020-05716-0. Epub ahead of print.
    • Germline Testing In Advanced Cancer Can Lead to Targeted Tx.
    • Nelson R.
    • Medscape. Conference News. 2020 Jun 2.
    • Germline Insights from NGS Somatic Testing: Clinical Challenges and Controversies.
    • Matloff ET, Giri VN, Nowak JA, Sotelo J, Silver DP.
    • Precision Oncology News. Resources: Webinars. 2020 Jun 1.
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    • Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC.
    • Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7.
    • Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer.
    • Alhopuro P, Vainionpää R, Anttonen AK, Aittomäki K, Nevanlinna H, Pöyhönen M.
    • Fam Cancer. 2020 May 28. doi: 10.1007/s10689-020-00186-1. Epub ahead of print.
    • High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
    • Mazzuccato G, De Bonis M, Carboni V, Marchetti C, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.
    • Mol Biol Rep. 2020 May 28. doi: 10.1007/s11033-020-05504-5. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Missed Mutations Highlight Somatic, Germline Test Difference.
    • Ray T.
    • Precision Oncology News. 2020 May 26.
    • High-throughput functional evaluation of BRCA2 variants of unknown significance.
    • Ikegami M, Kohsaka S, Ueno T, Momozawa Y, Inoue S, Tamura K, Shimomura A, Hosoya N, Kobayashi H, Tanaka S, Mano H.
    • Nat Commun. 2020 May 22;11(1):2573. doi: 10.1038/s41467-020-16141-8.
    • Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing.
    • Ray T.
    • Precision Oncology News. 2020 May 21.
    • News

    Related:

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer
    • [No author given]
    • GenomeWeb. 2020 May 20.
    • FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer.
    • [No author given]
    • U.S. Food & Drug Administration. Drug Approvals. 2020 May 20.

    Related:

    News: Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer (FORCE. XRAYS.)

    • Biomarker-Guided Development of DNA Repair Inhibitors.
    • Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD.
    • Mol Cell. 2020 May 17:S1097-2765(20)30277-X. doi: 10.1016/j.molcel.2020.04.035. Epub ahead of print.
    • Review
    • Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    • Chan AM, Enwere E, McIntyre JB, Wilson H, Nwaroh C, Wiebe N, Ou Y, Liu S, Wiedemeyer K, Rambau PF, Grevers X, Morris DG, Neri P, Gilks CB, Visser F, Le N, Luo L, Cook LS, Köbel M.
    • J Pathol Clin Res. 2020 May 11. doi: 10.1002/cjp2.168. Epub ahead of print.
    • The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis.
    • Crumbaker M, Chan EKF, Gong T, Corcoran N, Jaratlerdsiri W, Lyons RJ, Haynes AM, Kulidjian AA, Kalsbeek AMF, Petersen DC, Stricker PD, Jamieson CAM, Croucher PI, Hovens CM, Joshua AM, Hayes VM.
    • Cancers (Basel). 2020 May 7;12(5):E1178. doi: 10.3390/cancers12051178.
    • Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).
    • Li MM, Chao E, Esplin ED, Miller DT, Nathanson KL, Plon SE, Scheuner MT, Stewart DR; ACMG Professional Practice and Guidelines Committee.
    • Genet Med. 2020 Apr 23. doi: 10.1038/s41436-020-0783-8. Epub ahead of print.

    Related:

    News, Interview: Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing. (Precision Oncology News)

    • Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial.
    • McDonald ES, Doot RK, Pantel AR, Farwell MD, Mach RH, Maxwell KN, Mankoff DA.
    • JAMA Oncol. 2020 Apr 16. doi: 10.1001/jamaoncol.2020.0334. [Epub ahead of print]
    • Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
    • Choi MC, Hwang S, Kim S, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim TH, Kang H, An HJ.
    • Cancer Res Treat. 2020 Apr;52(2):634-644. doi: 10.4143/crt.2019.207. Epub 2020 Jan 6.
    • An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    • Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.
    • BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
    • Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    • Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ.
    • BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
    • Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer.
    • You Y, Li L, Lu J, Wu H, Wang J, Gao J, Wu M, Liang Z.
    • Front Oncol. 2020 Mar 10;10:295. doi: 10.3389/fonc.2020.00295. eCollection 2020.
    • Involving patients and their families in deciding to use next generation sequencing: Results from a nationally representative survey of U.S. oncologists.
    • Spees LP, Roberts MC, Freedman AN, Butler EN, Klein WMP, Prabhu Das I, de Moor JS.
    • Patient Educ Couns. 2020 Mar 3. pii: S0738-3991(20)30116-6. doi: 10.1016/j.pec.2020.03.001. [Epub ahead of print]
    • Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
    • Chevalier LM, Billaud A, Fronteau S, Dauvé J, Patsouris A, Verriele V, Morel A.
    • Mol Diagn Ther. 2020 Mar 2. doi: 10.1007/s40291-020-00452-z. [Epub ahead of print]
    • A profile on the FoundationFocus CDxBRCA tests.
    • Ford L, Wolford JE, Brown SM, Randall LM.
    • Expert Rev Mol Diagn. 2020 Mar;20(3):285-292. doi: 10.1080/14737159.2020.1701438. Epub 2020 Feb 6.
    • Review
    • Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer.
    • Aust S, Schwameis R, Gagic T, Müllauer L, Langthaler E, Prager G, Grech C, Reinthaller A, Krainer M, Pils D, Grimm C, Polterauer S.
    • Cancers (Basel). 2020 Feb 27;12(3). pii: E548. doi: 10.3390/cancers12030548.
    • Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
    • Sztupinszki Z, Diossy M, Krzystanek M, Börcsök , Pomerantz MM, Tisza V, Spisák S, Rusz O, Csabai I, Freedman ML, Szallasi Z.
    • Clin Cancer Res. 2020 Feb 18. pii: clincanres.2135.2019. doi: 10.1158/1078-0432.CCR-19-2135. [Epub ahead of print]
    • Despite Barriers, Labs Starting to Report Suspected Cancer Risk Mutations Seen in Tumor Testing.
    • Ray T.
    • GenomeWeb. 2020 Feb 6.
    • Understanding and information needs of cancer patients regarding treatment-focused genomic testing: A systematic review.
    • Wolyniec K, Sharp J, Lazarakis S, Mileshkin L, Schofield P.
    • Psychooncology. 2020 Feb 5. doi: 10.1002/pon.5351. [Epub ahead of print]
    • Review
    • Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report.
    • Julka PK, Verma A, Gupta K.
    • Case Rep Oncol. 2020 Feb 4;13(1):55-61. doi: 10.1159/000505182. eCollection 2020 Jan-Apr.
    • BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database.
    • Blanter J, Zimmerman B, Tharakan S, Ru M, Cascetta K, Tiersten A.
    • Oncology. 2020 Jan 21:1-4. doi: 10.1159/000504965. [Epub ahead of print]
    • Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
    • Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R.
    • Future Oncol. 2020 Jan 9. doi: 10.2217/fon-2019-0745. [Epub ahead of print]
    • Review, Commentary
    • Incorporating immunohistochemical markers into screening methods for BRCA1-mutated breast cancer.
    • Tuzimek A, Fudalej M, Sobiborowicz A, Budzik M, Badowska-Kozakiewicz A.
    • Pol J Pathol. 2020;71(3):261-269. doi: 10.5114/pjp.2020.99793.
    • Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    • Jorge S, McFaddin AS, Doll KM, Pennington KP, Norquist BM, Bennett RL, Pritchard CC, Swisher EM.
    • Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31802-5. doi: 10.1016/j.ygyno.2019.12.010. [Epub ahead of print]
    • Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.
    • Zhong R, Li H1, Liu Y, Zhang S, Liu J, Huang Z, Cheng Y.
    • Thorac Cancer. 2019 Dec 22. doi: 10.1111/1759-7714.13286. [Epub ahead of print]
    • Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
    • Whitehair R, Peres LC, Mills AM.
    • Int J Gynecol Pathol. 2019 Dec 16. doi: 10.1097/PGP.0000000000000657. [Epub ahead of print]
    • BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
    • Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, Jonasson JG, Eyfjord JE, Sigurdsson S.
    • JNCI Cancer Spectr. 2019 Dec 11;4(2):pkz100. doi: 10.1093/jncics/pkz100. eCollection 2020 Apr.
    • Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.
    • Carlo MI, Ravichandran V, Srinavasan P, Bandlamudi C, Kemel Y, Ceyhan-Birsoy O, Mukherjee S, Mandelker D, Chaim J, Knezevic A, Rana S, Fnu Z, Breen K, Arnold AG, Khurram A, Tkachuk K, Cipolla CK, Regazzi A, Hakimi AA, Al-Ahmadie H, Dalbagni G, Cadoo KA, Walsh MF, Teo MY, Funt SA, Coleman JA, Bochner BH, Iyer G, Solit DB, Stadler ZK, Zhang L, Rosenberg JE, Taylor BS, Robson ME, Berger MF, Vijai J, Bajorin DF, Offit K.
    • J Clin Oncol. 2019 Dec 3:JCO1901395. doi: 10.1200/JCO.19.01395. [Epub ahead of print]
    • Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).
    • Palacios J, de la Hoya M, Bellosillo B, de Juan I, Matías-Guiu X, Lázaro C, Palanca S, Osorio A, Rojo F, Rosa-Rosa JM, Cigudosa JC.
    • Virchows Arch. 2019 Dec 3. doi: 10.1007/s00428-019-02709-3. [Epub ahead of print]
    • Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response.
    • Franzese E, Centonze S, Diana A, Lombardi A, Carlino F, Guerrera LP, De Vita F, Caraglia M, Pignata S, Ciardiello F, Orditura M.
    • Front Oncol. 2019 Nov 29;9:1289. doi: 10.3389/fonc.2019.01289. eCollection 2019.
    • Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
    • Farolfi A, Lorusso D, Pignata S, De Giorgi U.
    • J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055. [Epub ahead of print]

    Related:

    Original research:

    Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

    • Automated Workflow for Somatic and Germline Next Generation Sequencing Analysis in Routine Clinical Cancer Diagnostics.
    • Muscarella LA, Fabrizio FP, De Bonis M, Mancini MT, Balsamo T, Graziano P, Centra F, Sparaneo A, Trombetta D, Bonfitto A, Scagliusi V, Larizza P, Capoluongo ED, Fazio VM.
    • Cancers (Basel). 2019 Oct 30;11(11). pii: E1691. doi: 10.3390/cancers11111691.
    • FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers.
    • Ray T.
    • GenomeWeb. 2019 Oct 29.
    • Cases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management.
    • Tischler J, Crew KD, Chung WK.
    • Ann Intern Med. 2019 Oct 22. doi: 10.7326/M18-2417. [Epub ahead of print]
    • Review
    • Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing.
    • Yamamoto Y, Kanai M, Kou T, Sugiyama A, Nakamura E, Miyake H, Yamada T, Nishigaki M, Kondo T, Murakami H, Torishima M, Matsumoto S, Kosugi S, Muto M.
    • J Hum Genet. 2019 Oct 18. doi: 10.1038/s10038-019-0681-6. [Epub ahead of print]
    • BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.
    • Capoluongo E, Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.
    • Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.
    • ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
    • Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL.
    • Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0569.2019. doi: 10.1158/1535-7163.MCT-19-0569. [Epub ahead of print]
    • Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial.
    • Shickh S, Clausen M, Mighton C, Gutierrez Salazar M, Zakoor KR, Kodida R, Reble E, Elser C, Eisen A, Panchal S, Aronson M, Graham T, Armel SR, Morel CF, Fattouh R, Glogowski E, Schrader KA, Hamilton JG, Offit K, Robson M, Carroll JC, Isaranuwatchai W, Kim RH, Lerner-Ellis J, Thorpe KE, Laupacis A, Bombard Y; Incidental Genomics Study Team.
    • BMJ Open. 2019 Oct 7;9(10):e031092. doi: 10.1136/bmjopen-2019-031092.
    • 'Landmark' Trial in Prostate Cancer With Mutations.
    • Davenport L.
    • Medscape Oncology. 2019 Oct 4.
    • Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.
    • Lee YJ, Kim D, Kim HS, Na K, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    • Yonsei Med J. 2019 Oct;60(10):914-923. doi: 10.3349/ymj.2019.60.10.914.
    • Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?
    • Pietragalla A, Minucci A, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2019 Sep 19. pii: ijgc-2019-000757. doi: 10.1136/ijgc-2019-000757. [Epub ahead of print]
    • Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
    • Fumagalli C, Rappa A, Casadio C, Betella I, Colombo N, Barberis M, Guerini-Rocco E.
    • J Clin Pathol. 2019 Sep 19. pii: jclinpath-2019-206127. doi: 10.1136/jclinpath-2019-206127. [Epub ahead of print]
    • Available and emerging molecular markers in the clinical management of breast cancer.
    • Giridhar KV, Liu MC.
    • Expert Rev Mol Diagn. 2019 Sep 9. doi: 10.1080/14737159.2019.1664901. [Epub ahead of print]
    • Review
    • Inherited cancer syndromes in 220 Italian ovarian cancer patients.
    • Carnevali I, Riva C, Chiaravalli AM, Sahnane N, Di Lauro E, Viel A, Rovera F, Formenti G, Ghezzi F, Sessa F, Tibiletti MG.
    • Cancer Genet. 2019 Sep;237:55-62. doi: 10.1016/j.cancergen.2019.06.005. Epub 2019 Jun 12.
    • Precision medicine for metastatic colorectal cancer: an evolving era.
    • Guler I, Askan G, Klostergaard J, Sahin IH.
    • Expert Rev Gastroenterol Hepatol. 2019 Aug 31. doi: 10.1080/17474124.2019.1663174. [Epub ahead of print]
    • Review
    • Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study.
    • Li W, Shao D, Li L, Wu M, Ma S, Tan X, Zhong S, Guo F, Wang Z, Ye M.
    • J Ovarian Res. 2019 Aug 31;12(1):80. doi: 10.1186/s13048-019-0560-y.
    • Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.
    • Casasanta N, Kipnis ST, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R.
    • Clin Breast Cancer. 2019 Aug 21. pii: S1526-8209(19)30646-9. doi: 10.1016/j.clbc.2019.07.004. [Epub ahead of print]
    • BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
    • Lee A, Kang J, Lee H, Lee YS, Choi YJ, Lee KH, Nistala GJ, Scafe CR, Choi J, Yoo J, Han M D E, Kim Y, Kim M.
    • Pathol Res Pract. 2019 Aug 16:152595. doi: 10.1016/j.prp.2019.152595. [Epub ahead of print]
    • Homologous recombination DNA repair defects in PALB2-associated breast cancers.
    • Li A, Geyer FC, Blecua P, Lee JY, Selenica P, Brown DN, Pareja F, Lee SSK, Kumar R, Rivera B, Bi R, Piscuoglio S, Wen HY, Lozada JR, Gularte-Mérida R, Cavallone L; kConFab Investigators, Rezoug Z, Nguyen-Dumont T, Peterlongo P, Tondini C, Terkelsen T, Rønlund K, Boonen SE, Mannerma A, Winqvist R, Janatova M, Rajadurai P, Xia B, Norton L, Robson ME, Ng PS, Looi LM, Southey MC, Weigelt B, Soo-Hwang T, Tischkowitz M, Foulkes WD, Reis-Filho JS.
    • NPJ Breast Cancer. 2019 Aug 8;5:23. doi: 10.1038/s41523-019-0115-9. eCollection 2019.
    • An optimized BRCA1/2 next-generation sequencing for different clinical sample types.
    • Kim Y, Cho CH, Ha JS, Kim DH, Kwon SY, Oh SC, Lee KA.
    • J Gynecol Oncol. 2019 Aug 6. doi: 10.3802/jgo.2020.31.e9. [Epub ahead of print]
    • Genomics applied to the treatment of breast cancer.
    • Hamdan D, Nguyen TT, Leboeuf C, Meles S, Janin A, Bousquet G.
    • Oncotarget. 2019 Jul 30;10(46):4786-4801. doi: 10.18632/oncotarget.27102. eCollection 2019 Jul 30.
    • From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin.
    • Pujol P, De La Motte Rouge T, Penault-Llorca F.
    • Diagnostics (Basel). 2019 Jul 26;9(3). pii: E83. doi: 10.3390/diagnostics9030083.
    • Framework Ranks 'Actionability' of Genetic Mutations for Precision Medicine.
    • Kerr DJ.
    • Medscape Oncology. 2019 Jul 18.

    Related:

    Original research:

    Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

    • Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
    • Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ.
    • Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30244-3. doi: 10.1016/j.urolonc.2019.06.015. [Epub ahead of print]
    • FoundationOne CDx Approved as Companion Diagnostic to Lynparza in Ovarian Cancer.
    • [No author given.]
    • Clinical Omics. 2019 Jul 3.
    • Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer.
    • [No author given]
    • GenomeWeb. 2019 Jun 19.
    • Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    • Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.
    • J Clin Oncol. 2019 Jun 19:JCO1901009. doi: 10.1200/JCO.19.01009. [Epub ahead of print]

    Related:

    Letter, Commentary:

    Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.

    • Chromosome 12p amplification in triple-negative/BRCA1-mutated breast cancer associates with emergence of docetaxel resistance and carboplatin sensitivity.
    • Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Solé A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monsó MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E.
    • Cancer Res. 2019 Jun 18. pii: canres.3835.2018. doi: 10.1158/0008-5472.CAN-18-3835. [Epub ahead of print]
    • Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.
    • Slavin TP, Coffee B, Bernhisel R, Logan J, Cox HC, Marcucci G, Weitzel J, Neuhausen SL, Mancini-DiNardo D.
    • Cancer Genet. 2019 Jun;235-236:31-38. doi: 10.1016/j.cancergen.2019.04.005. Epub 2019 Apr 13.
    • Liquid biopsy in breast cancer: A comprehensive review.
    • Alimirzaie S, Bagherzadeh M, Akbari MR.
    • Clin Genet. 2019 Jun;95(6):643-660. doi: 10.1111/cge.13514. Epub 2019 Jan 22.
    • Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    • Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.
    • Crit Rev Oncol Hematol. 2019 May 25;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. [Epub ahead of print]
    • Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    • Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid L, Reed AEM, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab); Australian Breast Cancer Tissue Bank (ABCTB); Brisbane Breast Bank (BBB), Beesley J, Harris J, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT.
    • Ann Oncol. 2019 May 15. pii: mdz132. doi: 10.1093/annonc/mdz132. [Epub ahead of print]

    Related:

    Editorial:

    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.

    • Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N.
    • J Natl Cancer Inst. 2019 May 11. pii: djz080. doi: 10.1093/jnci/djz080. [Epub ahead of print]

    Related:

    Letter, Comment:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Germline PALB2 heterozygous mutations in breast cancers: Haploinsufficiency paradigm.
    • Ouyang Q, Hu ZY, Liu L, Gao J, Wu H, Lu J, Xie N, Tian C, Liu Z, Xu Y.
    • Ann Oncol. 2019 May;30 Suppl 3:iii11-iii12. doi: 10.1093/annonc/mdz095.032. Epub 2020 Jan 8.
    • Conference abstract
    • Whole genome sequencing of breast cancer.
    • Rossing M, Sørensen CS, Ejlertsen B, Nielsen FC.
    • APMIS. 2019 May;127(5):303-315. doi: 10.1111/apm.12920. Epub 2019 Jan 28.
    • Identifying disparities in germline and somatic testing for ovarian cancer.
    • Huang M, Kamath P, Schlumbrecht M, Miao F, Driscoll D, Oldak S, Slomovitz B, Koru-Sengul T, George S.
    • Gynecol Oncol. 2019 May;153(2):297-303. doi: 10.1016/j.ygyno.2019.03.007. Epub 2019 Mar 16.
    • ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    • Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA, Madhusudan S.
    • Gynecol Oncol. 2019 May;153(2):416-424. doi: 10.1016/j.ygyno.2019.02.014. Epub 2019 Feb 20.
    • DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
    • Lotan TL, Kaur HB, Alharbi AM, Pritchard CC, Epstein JI.
    • Histopathology. 2019 May;74(6):836-843. doi: 10.1111/his.13806. Epub 2019 Apr 1.
    • Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    • Zakrzewski F, Gieldon L, Rump A, Seifert M, Grützmann K, Krüger A, Loos S, Zeugner S, Hackmann K, Porrmann J, Wagner J, Kast K, Wimberger P, Baretton G, Schröck E, Aust D, Klink B.
    • BMC Cancer. 2019 Apr 27;19(1):396. doi: 10.1186/s12885-019-5584-6.
    • Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    • Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P.
    • J Med Genet. 2019 Apr 12. pii: jmedgenet-2018-105930. doi: 10.1136/jmedgenet-2018-105930. [Epub ahead of print]
    • Germline Genetic Testing: What the Breast Surgeon Needs to Know.
    • Plichta JK, Sebastian ML, Smith LA, Menendez CS, Johnson AT, Bays SM, Euhus DM, Clifford EJ, Jalali M, Kurtzman SH, Taylor WA, Hughes KS.
    • Ann Surg Oncol. 2019 Apr 2. doi: 10.1245/s10434-019-07341-8. [Epub ahead of print]
    • Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
    • Gornjec A, Novakovic S, Stegel V, Hocevar M, Pohar Marinsek Z, Gazic B, Krajc M, Skof E.
    • BMC Cancer. 2019 Apr 2;19(1):296. doi: 10.1186/s12885-019-5535-2.
    • U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
    • Dottino JA, Moss HA, Lu KH, Secord AA, Havrilesky LJ.
    • Obstet Gynecol. 2019 Apr;133(4):795-802. doi: 10.1097/AOG.0000000000003171.
    • BRCA1/2 mutation spectrum in Chinese early-onset breast cancer.
    • Shen M, Yang L, Lei T, Xiao L, Li L, Zhang P, Feng W, Ye F, Bu H.
    • Transl Cancer Res. 2019 Apr;8(2):483-490. doi: 10.21037/tcr.2019.03.02.
    • A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer.
    • Forbes C, Fayter D, de Kock S, Quek RG.
    • Cancer Manag Res. 2019 Mar 22;11:2321-2337. doi: 10.2147/CMAR.S189627. eCollection 2019.
    • Germline susceptibility variants impact clinical outcome and therapeutic strategies for stage III colorectal cancer.
    • Lin PC, Yeh YM, Wu PY, Hsu KF, Chang JY, Shen MR.
    • Sci Rep. 2019 Mar 8;9(1):3931. doi: 10.1038/s41598-019-40571-0.
    • Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    • Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC.
    • Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.

    Related:

    Commentary: Framework Ranks 'Actionability' of Genetic Mutations for Precision Medicine (Medscape Oncology)

    • BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
    • Kwong A, Cheng KD, Hsue CV, Hui SK, Leung CR, Leung KA, Ngan KR, Soong SI.
    • Asia Pac J Clin Oncol. 2019 Mar;15 Suppl 2:20-31. doi: 10.1111/ajco.13116. Epub 2019 Mar 6.
    • [A Case of Early-Onset Breast Cancer for Which the Operative Indication for Breast Conservation Was Based on BRCA Genetic Testing].
    • Oki T, Sugimoto T, Ogawa M, Dabanaka K, Hanazaki K.
    • Gan To Kagaku Ryoho. 2019 Mar;46(3):555-557.
    • Case report, [Article in Japanese]
    • Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
    • Janni W, Schneeweiss A, Müller V, Wöckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Ettl J.
    • Geburtshilfe Frauenheilkd. 2019 Mar;79(3):268-280. doi: 10.1055/a-0842-6661. Epub 2019 Mar 12.
    • Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing.
    • Grimm C, Fischer A, Farrelly AM, Kalachand R, Castiglione R, Wasserburger E, Hussong M, Schultheis AM, Altmüller J, Thiele H, Reinhardt HC, Hauschulz K, Hennessy BT, Herwig R, Lienhard M, Buettner R, Schweiger MR.
    • J Mol Diagn. 2019 Mar;21(2):198-213. doi: 10.1016/j.jmoldx.2018.10.007. Epub 2018 Dec 19.
    • Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report.
    • Suda K, Nakaoka H, Hata C, Yahata N, Isobe M, Kameyama H, Wakai T, Motoyama T, Inoue I, Yoshihara K, Enomoto T.
    • Diagn Pathol. 2019 Feb 11;14(1):17. doi: 10.1186/s13000-019-0795-3.
    • Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
    • Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.
    • Int J Cancer. 2019 Feb 1;144(3):607-614. doi: 10.1002/ijc.31905. Epub 2018 Oct 22.
    • BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
    • Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.
    • Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.
    • [Biopathology of ovarian carcinomas early and advanced-stages: Article drafted from the French guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    • Devouassoux-Shisheboran M, Le Frère-Belda MA, Leary A.
    • Gynecol Obstet Fertil Senol. 2019 Feb;47(2):155-167. doi: 10.1016/j.gofs.2018.12.015. Epub 2019 Jan 25.
    • [Article in French]
    • Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies.
    • Barquín M, Maximiano C, Pérez-Barrios C, Sanchez-Herrero E, Soriano M, Colmena M, García-Espantaleón M, Tejerina González E, Gutierrez L, Sánchez Ruiz AC, Torrente M, Provencio M, Romero A.
    • Pathol Res Pract. 2019 Feb;215(2):392-394. doi: 10.1016/j.prp.2018.10.028. Epub 2018 Oct 28.
    • Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    • Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.
    • J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
    • Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer.
    • Veneris JT, Huang L, Churpek JE, Conzen SD, Fleming GF.
    • Int J Gynecol Cancer. 2019 Jan 25. pii: ijgc-2018-000101. doi: 10.1136/ijgc-2018-000101. [Epub ahead of print]
    • Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant.
    • De Bonis M, Minucci A, Scaglione GL, De Paolis E, Zannoni G, Scambia G, Capoluongo E.
    • Fam Cancer. 2019 Jan;18(1):29-35. doi: 10.1007/s10689-018-0094-2.
    • The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    • Hjortkjær M, Malik Aagaard Jørgensen M, Waldstrøm M, Ørnskov D, Søgaard-Andersen E, Jakobsen A, Dahl-Steffensen K.
    • Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.
    • Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing.
    • Clark DF, Maxwell KN, Powers J, Lieberman DB, Ebrahimzadeh J, Long JM, McKenna D, Shah P, Bradbury A, Morrissette JJD, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00076. Epub 2019 Aug 19.
    • Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study.
    • Kowalik A, Zalewski K, Kopczyński J, Siołek M, Lech M, Hińcza K, Kalisz J, Chrapek M, Zięba S, Furmańczyk J, Jedliński M, Chłopek M, Misiek M, Góźdź S.
    • Pol J Pathol. 2019;70(2):115-126. doi: 10.5114/pjp.2019.82905.
    • Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.
    • Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, Dinjens WNM, Lips E, Nederlof PM, Smid M, van de Werken HJG, Kanaar R, Martens JWM, Jager A, van Gent DC.
    • Clin Cancer Res. 2018 Dec 15;24(24):6277-6287. doi: 10.1158/1078-0432.CCR-18-0063. Epub 2018 Aug 23.
    • Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer.
    • McCuaig JM, Armel SR, Care M, Volenik A, Kim RH, Metcalfe KA.
    • Cancers (Basel). 2018 Nov 13;10(11). pii: E435. doi: 10.3390/cancers10110435.
    • The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
    • Sorscher S.
    • Oncologist. 2018 Nov;23(11):1266-1268. doi: 10.1634/theoncologist.2017-0681. Epub 2018 Jun 4.
    • Case report
    • Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.
    • An Y, Bi F, You Y, Liu X, Yang Q.
    • J Cancer. 2018 Oct 18;9(21):4058-4071. doi: 10.7150/jca.25587. eCollection 2018.
    • BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine.
    • Tlemsani C, Pasmant E, Boudou-Rouquett P, Bellesoeur A, Even J, Larousserie F, Reyes C, Gentien D, Alexandre J, Vidaud M, Anract P, Leroy K, Goldwasser F.
    • Am J Med Sci. 2018 Oct;356(4):404-407. doi: 10.1016/j.amjms.2018.04.015. Epub 2018 May 1.
    • Case report, Review
    • BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.
    • Mori H, Kubo M, Kai M, Velasquez VV, Kurata K, Yamada M, Okido M, Kuroki S, Oda Y, Nakamura M.
    • Clin Breast Cancer. 2018 Oct;18(5):e1217-e1227. doi: 10.1016/j.clbc.2018.05.008. Epub 2018 Jun 2.
    • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
    • Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.
    • Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.
    • A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    • Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.
    • Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.
    • Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas.
    • Buckley AR, Ideker T, Carter H, Harismendy O, Schork NJ.
    • Genome Med. 2018 Sep 14;10(1):69. doi: 10.1186/s13073-018-0579-5.
    • Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
    • Li G, Guo X, Chen M, Tang L, Jiang H, Day JX, Xie Y, Peng L, Xu X, Li J, Wang S, Xiao Z, Dai L, Wang J.
    • PLoS One. 2018 Sep 13;13(9):e0203495. doi: 10.1371/journal.pone.0203495. eCollection 2018.
    • Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
    • Vos S, Elias SG, van der Groep P, Smolders YH, van Gils CH, van Diest PJ.
    • Am J Surg Pathol. 2018 Sep;42(9):1262-1272. doi: 10.1097/PAS.0000000000001115.
    • BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    • Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.
    • Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.
    • Inherited gynaecological cancers.
    • George A.
    • Curr Opin Oncol. 2018 Sep;30(5):317-322. doi: 10.1097/CCO.0000000000000465.
    • Review
    • Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue.
    • de Jonge MM, Ruano D, van Eijk R, van der Stoep N, Nielsen M, Wijnen JT, Ter Haar NT, Baalbergen A, Bos MEMM, Kagie MJ, Vreeswijk MPG, Gaarenstroom KN, Kroep JR, Smit VTHBM, Bosse T, van Wezel T, van Asperen CJ.
    • J Mol Diagn. 2018 Sep;20(5):600-611. doi: 10.1016/j.jmoldx.2018.05.005. Epub 2018 Jun 21.
    • Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.
    • Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK.
    • Oncologist. 2018 Sep;23(9):998-1003. doi: 10.1634/theoncologist.2017-0645. Epub 2018 Apr 5.
    • Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    • da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE.
    • Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s. doi: 10.6061/clinics/2018/e450s.
    • Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
    • Mamounas EP, Russell CA, Lau A, Turner MP, Albain KS.
    • NPJ Breast Cancer. 2018 Aug 20;4:27. doi: 10.1038/s41523-018-0082-6. eCollection 2018.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di LJ.
    • Clin Cancer Res. 2018 Aug 1;24(15):3560-3571. doi: 10.1158/1078-0432.CCR-17-3862. Epub 2018 Apr 16.
    • Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
    • Murciano-Goroff YR, McCarthy AM, Bristol MN, Groeneveld P, Domchek SM, Motanya UN, Armstrong K.
    • Breast Cancer Res Treat. 2018 Aug;171(1):173-180. doi: 10.1007/s10549-018-4810-2. Epub 2018 May 8.
    • FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
    • Wilkins A, Chauhan R, Rust A, Pearson A, Daley F, Manodoro F, Fenwick K, Bliss J, Yarnold J, Somaiah N.
    • Breast Cancer Res Treat. 2018 Aug;170(3):573-581. doi: 10.1007/s10549-018-4798-7. Epub 2018 Feb 22.
    • Therapeutic landscape in mutational triple negative breast cancer.
    • Shi Y, Jin J, Ji W, Guan X.
    • Mol Cancer. 2018 Jul 14;17(1):99. doi: 10.1186/s12943-018-0850-9.
    • Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.
    • Chanez B, Chaffanet M, Adélaide J, Thomassin J, Garnier S, Carbuccia N, Guille A, Charrier N, Brenot-Rossi I, Walz J, Pignot G, Pakradouni J, Gonçalvès A, Eisinger F, Bertucci F, Birnbaum D, Gravis G.
    • JCO Precis Oncol. 2018 Nov [Epub 2018 Jul 10];2:1-8. doi: 10.1200/PO.18.00083.
    • Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
    • Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R.
    • Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.
    • Interleukin enhancer binding factor 2 is a prognostic biomarker for breast cancer that also predicts neoadjuvant chemotherapy responses.
    • Jin Z, Xu L, Zhang L, Zhao M, Li D, Ye L, Ma Y, Ren S, Yu H, Wang D, Liang C, Chen B.
    • Am J Transl Res. 2018 Jun 15;10(6):1677-1689. eCollection 2018.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di L
    • Clin Cancer Res. 2018 Jun 12. doi: 10.1158/1078-0432.CCR-17-3862. [Epub ahead of print]
    • High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report.
    • Costella A, De Leo R, Guarino D, D'Indinosante M, Concolino P, Mazzuccato G, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.
    • Hum Genome Var. 2018 Jun 8;5:10. doi: 10.1038/s41439-018-0006-x. eCollection 2018.
    • Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation.
    • Dizon DS, Dias-Santagata D, Bregar A, Sullivan L, Filipi J, DiTavi E, Miller L, Ellisen L, Birrer M, DelCarmen M.
    • Oncologist. 2018 Jun;23(6):650-653. doi: 10.1634/theoncologist.2017-0526. Epub 2018 Feb 22.
    • Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
    • Dai Y, Sun C, Feng Y, Jia Q, Zhu B.
    • J Cell Mol Med. 2018 May 31. doi: 10.1111/jcmm.13678. [Epub ahead of print]
    • Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.
    • Losi L, Fonda S, Saponaro S, Chelbi ST, Lancellotti C, Gozzi G, Alberti L, Fabbiani L, Botticelli L, Benhattar J.
    • Int J Mol Sci. 2018 May 24;19(6). pii: E1559. doi: 10.3390/ijms19061559.
    • Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.
    • Cheng H, Powers J, Schaffer K, Sartor O.
    • Am Soc Clin Oncol Educ Book. 2018 May 23;(38):372-381. doi: 10.1200/EDBK_205441.
    • Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
    • Fan FS, Yang CF.
    • J Med Case Rep. 2018 May 6;12(1):122. doi: 10.1186/s13256-018-1674-3.
    • Metabolomic profiles in breast cancer:a pilot case-control study in the breast cancer family registry.
    • Dougan MM, Li Y, Chu LW, Haile RW, Whittemore AS, Han SS, Moore SC, Sampson JN, Andrulis IL, John EM, Hsing AW.
    • BMC Cancer. 2018 May 5;18(1):532. doi: 10.1186/s12885-018-4437-z.
    • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.
    • Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.
    • A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
    • Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL.
    • J Clin Invest. 2018 May 1;128(5):2116-2126. doi: 10.1172/JCI97992. Epub 2018 Apr 16.

    Related:

    Identifier: NCT02637934: Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT. (ClinicalTrials.gov)

    Commentary:

    The evolving landscape of predictive biomarkers of response to PARP inhibitors.

    • Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.
    • Rechsteiner M, Dedes K, Fink D, Pestalozzi B, Sobottka B, Moch H, Wild P, Varga Z.
    • J Cancer Res Clin Oncol. 2018 May;144(5):865-874. doi: 10.1007/s00432-018-2609-5. Epub 2018 Feb 17.
    • Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.
    • Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, Peretz T, Hubert A.
    • Mol Clin Oncol. 2018 May;8(5):683-685. doi: 10.3892/mco.2018.1588. Epub 2018 Mar 9.
    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    • Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder S, Bliss JM.v
    • Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.
    • SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
    • Xu L, Che X, Wu Y, Song N, Shi S, Wang S, Li C, Zhang L, Zhang X, Qu X, Teng Y.
    • Oncol Rep. 2018 May;39(5):2315-2323. doi: 10.3892/or.2018.6319. Epub 2018 Mar 16.
    • Role of tumor microenvironment in ovarian cancer pathobiology.
    • Ghoneum A, Afify H, Salih Z, Kelly M, Said N.
    • Oncotarget. 2018 Apr 27;9(32):22832-22849. doi: 10.18632/oncotarget.25126. eCollection 2018 Apr 27.
    • Main implications related to the switch to BRCA1/2 tumor testing in ovarian cancer patients: a proposal of a consensus.
    • Capoluongo E, Scambia G, Nabholtz JM.
    • Oncotarget. 2018 Apr 13;9(28):19463-19468. doi: 10.18632/oncotarget.24728. eCollection 2018 Apr 13.
    • [Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    • Oaknin A, Guarch R, Barretina P, Hardisson D, González-Martín A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
    • Rev Esp Patol. 2018 Apr - Jun;51(2):84-96. doi: 10.1016/j.patol.2017.11.002. Epub 2018 Jan 17.
    • Consensus statement, Review, [Article in Spanish]
    • Practical consensus recommendation on when to do BRCA testing.
    • Parikh PM, Wadhwa J, Minhas S, Gupta A, Mittal S, Ranjan S, Mehta P, Singh R, Kataria SP, Salim S, Ahmed M, Aggarwal S.
    • South Asian J Cancer. 2018 Apr-Jun;7(2):106-109. doi: 10.4103/sajc.sajc_112_18.
    • Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
    • Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN.
    • Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24.

    Related:

    Research news:

    Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

    • BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
    • Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S.
    • Clin Breast Cancer. 2018 Apr;18(2):184-188. doi: 10.1016/j.clbc.2017.12.010. Epub 2017 Dec 21.
    • Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    • Xiao X, Dong D, He W, Song L, Wang O, Yue J, Xie L.
    • Gynecol Oncol. 2018 Apr;149(1):146-154. doi: 10.1016/j . Epub 2018 Mar 1.
    • Targeting DNA repair: the genome as a potential biomarker.
    • Nesic K, Wakefield M, Kondrashova O, Scott CL, McNeish IA.
    • J Pathol. 2018 Apr;244(5):586-597. doi: 10.1002/path.5025. Epub 2018 Feb 10.
    • An evaluation of the challenges to developing tumour BRCA1 and BRCA2 testing methodologies for clinical practice.
    • Ellison G, Ahdesmäki M, Luke S, Waring PM, Wallace A, Wright R, Röthlisberger B, Ludin K, Merkelbach-Bruse S, Heydt C, Ligtenberg MJL, Mensenkamp AR, Castro DG, Jones T, Vivancos A, Kondrashova O, Pauwels P, Weyn C, Hahnen E, Hauke J, Soong R, Lai Z, Dougherty B, Carr TH, Johnson J, Mills J, Barrett JC.
    • Hum Mutat. 2018 Mar;39(3):394-405. doi: 10.1002/humu.23375. Epub 2017 Dec 28.
    • Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
    • Martín de la Fuente L, Malander S, Hartman L, Jönsson JM, Ebbesson A, Nilbert M, Måsbäck A, Hedenfalk I.
    • Int J Gynecol Pathol. 2018 Mar;37(2):101-109. doi: 10.1097/PGP.0000000000000394.
    • BRCA1 through Its E3 Ligase Activity Regulates the Transcription Factor Oct1 and Carbohydrate Metabolism.
    • Vázquez-Arreguín K, Maddox J, Kang J, Park D, Cano RR, Factor RE, Ludwig T, Tantin D.
    • Mol Cancer Res. 2018 Mar;16(3):439-452. doi: 10.1158/1541-7786.MCR-17-0364. Epub 2018 Jan 12.
    • Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.
    • Banda K, Swisher EM, Wu D, Pritchard CC, Gadi VK.
    • JCO Precis Oncol. 2018 Nov [2018 Feb 14];2:1-6. doi: 10.1200/PO.17.00044.

    Related:

    Commentary:

    Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.

    • MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.
    • Xie B, Yuan Z, Yang Y, Sun Z, Zhou S, Fang X.
    • Breast Cancer Res Treat. 2018 Feb 10. doi: 10.1007/s10549-018-4708-z. [Epub ahead of print]
    • Database report
    • BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    • Brianese RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, Barros BDF, Ferreira ENE, Formiga MNDC, de Andrade VP, de Lima VCC, Carraro DM.
    • Breast Cancer Res Treat. 2018 Feb;167(3):803-814. doi: 10.1007/s10549-017-4552-6. Epub 2017 Nov 7.
    • Expression of βV-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia.
    • Mathew D, Wang Y, Van Arsdale A, Horwitz SB, McDaid H.
    • Int J Gynecol Cancer. 2018 Feb;28(2):363-370. doi: 10.1097/IGC.0000000000001160.
    • Gynaecological neoplasms in common familial syndromes (Lynch and HBOC).
    • Bartosch C, Clarke B, Bosse T.
    • Pathology. 2018 Feb;50(2):222-237. doi: 10.1016/j.pathol.2017.10.010. Epub 2017 Dec 26.
    • Review
    • Characterization of basal-like subtype in a Danish consecutive primary breast cancer cohort.
    • Kinalis S, Nielsen FC, Talman ML, Ejlertsen B, Rossing M.
    • Acta Oncol. 2018 Jan;57(1):51-57. doi: 10.1080/0284186X.2017.1398837. Epub 2017 Nov 22.
    • Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer.
    • Danzinger S, Tan YY, Rudas M, Kastner MT, Weingartshofer S, Muhr D, Singer CF; kConFab Investigators.
    • Cancer Invest. 2018;36(7):378-388. doi: 10.1080/07357907.2018.1499934. Epub 2018 Aug 24.
    • Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data.
    • Khiabanian H, Hirshfield KM, Goldfinger M, Bird S, Stein M, Aisner J, Toppmeyer D, Wong S, Chan N, Dhar K, Gheeya J, Vig H, Hadigol M, Pavlick D, Ansari S, Ali S, Xia B, Rodriguez-Rodriguez L, Ganesan S.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00148. Epub 2018 Jan 19.
    • SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.
    • Warner JL, Prasad I, Bennett M, Arniella M, Beeghly-Fadiel A, Mandl KD, Alterovitz G.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00292. Epub 2018 May 1.
    • Simultaneous detection of genetic and copy number alterations in BRCA1/2 genes.
    • Hirotsu Y, Ooka Y, Sakamoto I, Nakagomi H, Omata M.
    • Oncotarget. 2017 Dec 6;8(70):114463-114473. doi: 10.18632/oncotarget.22962. eCollection 2017 Dec 29.
    • Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
    • Berchuck A, Secord AA, Moss HA, Havrilesky LJ.
    • J Clin Oncol. 2017 Dec 20;35(36):3999-4002. doi: 10.1200/JCO.2017.74.5752. Epub 2017 Oct 26.
    • Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
    • Roig B, Rodríguez-Balada M, Samino S, Lam EW, Guaita-Esteruelas S, Gomes AR, Correig X, Borràs J, Yanes O, Gumà J.
    • Sci Rep. 2017 Dec 19;7(1):17831. doi: 10.1038/s41598-017-17897-8.
    • Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    • Zhao EY, Shen Y, Pleasance E, Kasaian K, Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, Corbett R, Mungall KL, Thiessen N, Ma Y, Schein JE, Mungall AJ, Zhao Y, Moore RA, Den Brok W, Wilson S, Villa D, Shenkier T, Lohrisch C, Chia S, Yip S, Gelmon K, Lim H, Renouf D, Sun S, Schrader KA, Young S, Bosdet I, Karsan A, Laskin J, Marra MA, Jones SJM.
    • Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. doi: 10.1158/1078-0432.CCR-17-1941.
    • Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer.
    • Ratajska M, Koczkowska M, Żuk M, Gorczyński A, Kuźniacka A, Stukan M, Biernat W, Limon J, Wasąg B.
    • Oncotarget. 2017 Sep 8;8(60):101325-101332. doi: 10.18632/oncotarget.20722. eCollection 2017 Nov 24.
    • The roles of pathology in targeted therapy of women with gynecologic cancers.
    • Murali R, Grisham RN, Soslow RA.
    • Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530-5. doi: 10.1016/j.ygyno.2017.11.020. [Epub ahead of print]
    • Review
    • Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
    • Wang Y, Ung MH, Cantor S, Cheng C.
    • Sci Rep. 2017 Nov 16;7(1):15742. doi: 10.1038/s41598-017-16138-2.
    • Who are the long-term survivors of high grade serous ovarian cancer?
    • Hoppenot C, Eckert MA, Tienda SM, Lengyel E.
    • Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31454-3. doi: 10.1016/j.ygyno.2017.10.032. [Epub ahead of print]
    • Review
    • Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    • Lanz HL, Saleh A, Kramer B, Cairns J, Ng CP, Yu J, Trietsch SJ, Hankemeier T, Joore J, Vulto P, Weinshilboum R, Wang L.
    • BMC Cancer. 2017 Nov 2;17(1):709. doi: 10.1186/s12885-017-3709-3.
    • Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
    • Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, Garcia-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J1, Reis-Filho JS, Greenberg RA, Robson M, Turner NC.
    • Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.
    • Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    • Vanderstichele A, Busschaert P, Olbrecht S, Lambrechts D, Vergote I.
    • Eur J Cancer. 2017 Nov;86:5-14. doi: 10.1016/j.ejca.2017.08.029. Epub 2017 Sep 23.
    • Combining Enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness.
    • Thompson TC, Li L, Broom BM.
    • Oncotarget. 2017 Oct 25. doi: 10.18632/oncotarget.22074. [Epub ahead of print]
    • Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
    • Thomas SN, Chen L, Liu Y, Hoti N, Zhang H.
    • J Proteome Res. 2017 Oct 6;16(10):3704-3710. doi: 10.1021/acs.jproteome.7b00405. Epub 2017 Sep 14.
    • Hypoxia-induced factor-1 alpha, vascular endothelial growth factor expression in BRCA1-related breast cancer: A prospective study in tertiary care hospital.
    • Sharma M, Piplani S, Madan M, Manjari M, Garg S, Kaur K.
    • Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):469-474. doi: 10.4103/IJPM.IJPM_524_16.
    • Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
    • Li G, Guo X, Tang L, Chen M, Luo X, Peng L, Xu X, Wang S, Xiao Z, Yi W, Dai L, Wang J.
    • J Cancer Res Clin Oncol. 2017 Oct;143(10):2011-2024. doi: 10.1007/s00432-017-2465-8. Epub 2017 Jun 29.
    • Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients.
    • Jeong HM, Kim RN, Kwon MJ, Oh E, Han J, Lee SK, Choi JS, Park S, Nam SJ, Gong GY, Nam JW, Choi DH, Lee H, Nam BH, Choi YL, Shin YK.
    • Oncotarget. 2017 Jun 27;8(37):61538-61550. doi: 10.18632/oncotarget.18618. eCollection 2017 Sep 22.
    • Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    • Klimov S, Rida PC, Aleskandarany MA, Green AR, Ellis IO, Janssen EA, Rakha EA, Aneja R.
    • Br J Cancer. 2017 Sep 5;117(6):826-834. doi: 10.1038/bjc.2017.224. Epub 2017 Jul 18.
    • Current Challenges Associated With Next-Generation Sequencing of Breast Cancer.
    • Sorscher S.
    • JAMA Oncol. 2017 Sep 1;3(9):1283-1284. doi: 10.1001/jamaoncol.2017.0659.
    • Letter, Comment

    Related:

    Review:

    The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review.

    Letter, Reply:

    Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply.

    • BRCA1 protein expression and subcellular localization in primary breast cancer: Automated digital microscopy analysis of tissue microarrays.
    • Mahmoud AM, Macias V, Al-Alem U, Deaton RJ, Kadjaksy-Balla A, Gann PH, Rauscher GH.
    • PLoS One. 2017 Sep 1;12(9):e0184385. doi: 10.1371/journal.pone.0184385. eCollection 2017.
    • Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.
    • Domchek SM.
    • Cancer Discov. 2017 Sep;7(9):937-939. doi: 10.1158/2159-8290.CD-17-0734.
    • Review

    Related:

    Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-grade Ovarian Carcinoma.

    Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.

    Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

    • Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-grade Ovarian Carcinoma.
    • Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza AM, Sun JX, Robillard L, Maloney L, Bowtell DDL, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin K, Scott CL.
    • Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

    Related:

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    • DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    • Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.
    • NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.
    • Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5.
    • Freedland S, Aronson W.
    • Urol Oncol. 2017 Aug;35(8):536. doi: 10.1016/j.urolonc.2017.05.011. Epub 2017 Jun 13.
    • Commentary

    Related:

    Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.

    • NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
    • Mangia A, Scarpi E, Partipilo G, Schirosi L, Opinto G, Giotta F, Simone G.
    • Oncotarget. 2017 Jul 22;8(39):65730-65742. doi: 10.18632/oncotarget.19444. eCollection 2017 Sep 12.
    • Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    • Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, Knight JA, Hsu L, Concannon P, Mellemkjær L, Tischkowitz M, Haile RW, Shen R, Malone KE, Woods M, Liang X, Morrow M, Bernstein JL; WECARE Study Collaborative Group.
    • Breast Cancer Res. 2017 Jul 19;19(1):83. doi: 10.1186/s13058-017-0874-x.
    • My Tumor Carries A BRCA Mutation. Does This Mean I’m A BRCA Carrier?
    • [No author given]
    • My Gene Counsel. 2017 Jul 7.
    • Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    • Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC.
    • Oncotarget. 2017 Jul 4;8(27):43653-43661. doi: 10.18632/oncotarget.17613.

    Related:

    Research news:

    Olaparib and somatic BRCA mutations.

    • Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer.
    • Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, Brufsky AM, Puhalla SL, Bhargava R.
    • Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):392-398. doi: 10.1097/PAI.0000000000000322.
    • Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    • Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW.
    • Eur Urol. 2017 Jul;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023. Epub 2017 Mar 1.
    • Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    • Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K; BGI Group.
    • J Gynecol Oncol. 2017 Jul;28(4):e39. doi: 10.3802/jgo.2017.28.e39.
    • Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
    • Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M.
    • J Neurooncol. 2017 Jul;133(3):469-476. doi: 10.1007/s11060-017-2459-z. Epub 2017 May 11.
    • Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.
    • Li G, Guo X, Tang L, Chen M, Luo X, Peng L, Xu X, Wang S, Xiao Z, Yi W, Dai L, Wang J.
    • J Cancer Res Clin Oncol. 2017 Jun 29. doi: 10.1007/s00432-017-2465-8. [Epub ahead of print]
    • BRCA1 reversion mutation acquired after treatment identified by liquid biopsy.
    • Mayor P, Gay LM, Lele S, Elvin JA.
    • Gynecol Oncol Rep. 2017 Jun 21;21:57-60. doi: 10.1016/j.gore.2017.06.010. eCollection 2017 Aug.
    • Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib.
    • Rizvi W, Truong P, Truong Q.
    • Cureus. 2017 Jun 11;9(6):e1337. doi: 10.7759/cureus.1337.
    • DNA repair genes PAXIP1 and TP53BP1 expression is associated with breast cancer prognosis.
    • De Gregoriis G, Ramos JA, Fernandes PV, Vignal GM, Brianese RC, Carraro DM, Monteiro AN, Struchiner C, Suarez-Kurtz G, Vianna-Jorge R, de Carvalho MA.
    • Cancer Biol Ther. 2017 Jun 3;18(6):439-449. doi: 10.1080/15384047.2017.1323590. Epub 2017 May 5.
    • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
    • Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R, van Asperen CJ, Ray-Coquard I, Endris V, Kamel-Reid S, Percival N, Bryce J, Röthlisberger B, Soong R, de Castro DG.
    • Semin Oncol. 2017 Jun;44(3):187-197. doi: 10.1053/j.seminoncol.2017.08.004. Epub 2017 Sep 15.
    • BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    • Vos S, Moelans CB, van Diest PJ.
    • Breast Cancer Res. 2017 May 31;19(1):64. doi: 10.1186/s13058-017-0856-z.
    • Genomic Testing and Precision Medicine in Cancer Care.
    • West HJ, Miller G.
    • Medscape. News & Perspective. 2017 May 2.
    • Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
    • Halpern N, Sonnenblick A, Uziely B, Divinsky L, Goldberg Y, Hamburger T, Peretz T, Kadouri L.
    • Int J Cancer. 2017 May 1;140(9):2145-2149. doi: 10.1002/ijc.30616. Epub 2017 Feb 8.
    • Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
    • Heublein S, Mayr D, Meindl A, Kircher A, Jeschke U, Ditsch N.
    • J Exp Clin Cancer Res. 2017 Apr 20;36(1):57. doi: 10.1186/s13046-017-0517-1.
    • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
    • Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.
    • Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.
    • Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.
    • McGrail DJ, Lin CC, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, Vellano CP, Hennessy B, Mills GB, Lin SY.
    • NPJ Syst Biol Appl. 2017 Mar 6;3:8. doi: 10.1038/s41540-017-0011-6. eCollection 2017.
    • The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
    • Hjortkjær M, Waldstrøm M, Jakobsen A, Kanstrup H, Søgaard-Andersen E, Dahl Steffensen K.
    • Int J Gynecol Pathol. 2017 Mar;36(2):180-189. doi: 10.1097/PGP.0000000000000310.
    • Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
    • Frey MK, Pothuri B.
    • Gynecol Oncol Res Pract. 2017 Feb 22;4:4. doi: 10.1186/s40661-017-0039-8. eCollection 2017.
    • The Role of Genetic Testing in the Selection of Therapy for Breast Cancer: A Review.
    • Niravath P, Cakar B, Ellis M.
    • JAMA Oncol. 2017 Feb 1;3(2):262-268. doi: 10.1001/jamaoncol.2016.2719.
    • Review

    Related:

    Letter, Comment:

    Current Challenges Associated With Next-Generation Sequencing of Breast Cancer.

    Related:

    Letter, Reply:

    Current Challenges Associated With Next-Generation Sequencing of Breast Cancer-Reply.

    • Novel BRCA1 and BRCA2 Tumour Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
    • Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, van Asseldonk M, Gomez-Garcia EB, Blok MJ, de Hullu JA, Nelen MR, Hoischen A, Bulten J, Tops BB, Hoogerbrugge N, Ligtenberg EM.
    • Hum Mutat. 2017 Feb;38(2):226-235. doi: 10.1002/humu.23137. Epub 2016 Nov 9.
    • Molecularly confirmed Li-Fraumeni-like syndrome in a patient with breast cancer and a low pre-test probability for harboring a germline CHEK2 truncation
    • Sorscher S
    • Integr Cancer Sci Ther. 2017 Feb;4(1). doi: 10.15761/ICST.1000224. Epub 2017 Feb 27.
    • Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.
    • Geurts-Giele WR, van Verschuer VM, van Deurzen CH, van Diest PJ, Pedrosa RM, Collée JM, Koppert LB, Seynaeve C, Dinjens WN.
    • Mod Pathol. 2017 Jan;30(1):15-25. doi: 10.1038/modpathol.2016.145. Epub 2016 Sep 9.
    • Molecular analysis of BRCA1 and BRCA2 genes by next generation sequencing and ultrastructural aspects of breast tumor tissue.
    • Mihalcea CE, Moroşanu AM, Murăraşu D, Puiu L, Cinca SA, Voinea SC, Mirancea N.
    • Rom J Morphol Embryol. 2017;58(2):445-455.
    • Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
    • Jiang T, Shi W, Wali VB, Pongor LS, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C.
    • PLoS Med. 2016 Dec 13;13(12):e1002193. doi: 10.1371/journal.pmed.1002193. eCollection 2016.
    • Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
    • Lemstrova R, Melichar B, Mohelnikova-Duchonova B.
    • Cancer Chemother Pharmacol. 2016 Dec;78(6):1101-1111. Epub 2016 Jun 1.
    • Review
    • BRCA1 expression in benign and malignant breast lesions.
    • Fernández Á, Reigosa A.
    • Invest Clin. 2016 Dec;57(4):330-51.
    • Population Frequency of Germline BRCA1/2 Mutations.
    • Maxwell KN, Domchek SM, Nathanson KL, Robson ME.
    • J Clin Oncol. 2016 Dec;34(34):4183-4185. Epub 2016 Oct 31.
    • Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers.
    • Rantalainen M, Klevebring D, Lindberg J, Ivansson E, Rosin G, Kis L, Celebioglu F, Fredriksson I, Czene K, Frisell J, Hartman J, Bergh J, Grönberg H.
    • Sci Rep. 2016 Nov 30;6:38037. doi: 10.1038/srep38037.
    • Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.
    • Chen S, Cavazza E, Barlier C, Salleron J, Filhine-Tresarrieu P, Gavoilles C, Merlin JL, Harlé A.
    • Oncol Lett. 2016 Nov;12(5):3264-3272. Epub 2016 Sep 2.
    • [BRCA1 and BRCA2 - pathologists starting kit].
    • Škapa P.
    • Cesk Patol. 2016 Fall;52(4):193-196.
    • [Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
    • Vošmiková H, Ryška A, Sieglová K, Laco J.
    • Cesk Patol. 2016 Fall;52(4):210-214.
    • Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    • Seifert BA, O'Daniel JM, Amin K, Marchuk DS, Patel NM, Parker JS, Hoyle AP, Mose LE, Marron A, Hayward MC, Bizon C, Wilhelmsen KC, Evans JP, Earp HS, Sharpless N, Hayes DN, Berg JS.
    • Clin Cancer Res. 2016 Aug 15;22(16):4087-94. doi: 10.1158/1078-0432.CCR-16-0015. Epub 2016 Apr 15.

    Related:

    Editorial / Commentary

    Toward Concurrent Testing for Somatic and Germline Variants in Cancer Patients.

    • Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests one third of mutations are somatic.
    • Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, Törngren T, Vallon-Christersson J, Hegardt C, Häkkinen J, Jönsson G, Grabau D, Malmberg M, Kristoffersson U, Rehn M, Gruvberger-Saal SK, Larsson C, Borg Å, Loman N, Saal LH.
    • Ann Oncol. 2016 Aug;27(8):1532-8. doi: 10.1093/annonc/mdw209. Epub 2016 May 18.
    • Molecular Testing in Breast Cancer: A Guide to Current Practices.
    • Hagemann IS.
    • Arch Pathol Lab Med. 2016 Aug;140(8):815-24. doi: 10.5858/arpa.2016-0051-RA.
    • Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients.
    • Zimmermann MT, Jiang G, Wang C.
    • AMIA Jt Summits Transl Sci Proc. 2016 Jul 20;2016:94-100. eCollection 2016.
    • Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice.
    • Dong A, Lu Y, Lu B.
    • J Cancer. 2016 Jul 5;7(11):1441-51. doi: 10.7150/jca.15556. eCollection 2016.
    • Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
    • Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, Hendler D, Neiman V, Ben-Aharon I, Friedman E, Paluch-Shimon S, Margel D, Kedar I, Yerushalmi R.
    • Breast Cancer Res Treat. 2016 Jun;157(3):511-6. doi: 10.1007/s10549-016-3836-6. Epub 2016 May 25.
    • Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
    • Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B.
    • Eur Urol. 2016 Jun;69(6):992-5. doi: 10.1016/j.eururo.2015.11.022. Epub 2015 Dec 24.

    Related:

    Commentary:

    Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5.

    • The Clinical Impact of BRCA2 Loss in Prostate Cancer.
    • Bryant HE.
    • Eur Urol. 2016 Jun;69(6):996-7. doi: 10.1016/j.eururo.2015.12.009. Epub 2015 Dec 18.
    • NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial.
    • Endris V, Stenzinger A, Pfarr N, Penzel R, Möbs M, Lenze D, Darb-Esfahani S, Hummel M, Sabine-Merkelbach-Bruse, Jung A, Lehmann U, Kreipe H, Kirchner T, Büttner R, Jochum W, Höfler G, Dietel M, Weichert W, Schirmacher P.
    • Virchows Arch. 2016 Jun;468(6):697-705. doi: 10.1007/s00428-016-1919-8. Epub 2016 Mar 22.
    • Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer.
    • Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, Zhong Z, Sun J.
    • Oncotarget. 2016 May 31;7(22):32433-48. doi: 10.18632/oncotarget.8653.
    • Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    • Decker B, Karyadi DM, Davis BW, Karlins E, Tillmans LS, Stanford JL, Thibodeau SN, Ostrander EA.
    • Am J Hum Genet. 2016 May 5;98(5):818-829. doi: 10.1016/j.ajhg.2016.03.003. Epub 2016 Apr 14.
    • Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
    • Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.
    • Nature. 2016 May 2;534(7605):47-54. doi: 10.1038/nature17676.

    Related:

    News: Breast cancer mutation map could aid personalised treatment (PHG Foundation)

    Press: Scientists say they now have a near-perfect picture of the genetic events that cause breast cancer. (BBC.com)

    Press: Personalized Breast Cancer Treatment Gets Closer to Reality (Time.com)

    • The Significance of Proteomic Biomarkers in Male Breast Cancer.
    • Zografos E, Gazouli M, Tsangaris G, Marinos E.
    • Cancer Genomics Proteomics. 2016 05-06 [2016 May-Jun;]13(3):183-190.
    • How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.
    • Lynce F, Isaacs C.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):e72-e78. doi: 10.1200/EDBK_160391.
    • Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    • Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME.
    • Cancer. 2016 Apr 15;122(8):1178-1184. doi: 10.1002/cncr.29903. Epub 2016 Feb 9.
    • Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
    • Alvarez C, Aravena A, Tapia T, Rozenblum E, Solís L, Corvalán A, Camus M, Alvarez M, Munroe D, Maass A, Carvallo P.
    • BMC Cancer. 2016 Mar 15;16(1):219. doi: 10.1186/s12885-016-2261-x.
    • Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course".
    • Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS.
    • J Natl Compr Canc Netw. 2016 Mar;14(3):lxvi-lxviii.
    • Letter

    Related:

    Case report

    Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.

    Response / Letter

    The Authors Respond.

    • Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
    • Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C.
    • J Natl Cancer Inst. 2016 Feb 4;108(7). pii: djv437. doi: 10.1093/jnci/djv437. Print 2016 Jul.
    • BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    • Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, Piazzola E, Sperandio N, Turri G, Franchi M, Tortora G, Bovo C, Lawlor RT, Scarpa A.
    • Oncotarget. 2016 Jan 12;7(2):1076-83. doi: 10.18632/oncotarget.6834.
    • Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    • Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.
    • Eur J Cancer. 2016 Jan;53:51-64. doi: 10.1016/j.ejca.2015.11.001. Epub 2015 Dec 13.
    • Genomic testing and precision medicine - What does this mean for gynecologic oncology?
    • Liu J, Konstantinopoulos PA, Matulonis UA.
    • Gynecol Oncol. 2016 Jan;140(1):3-5. doi: 10.1016/j.ygyno.2015.12.001. Epub 2015 Dec 4.
    • The cancer genetics and pathology of male breast cancer.
    • Deb S, Lakhani SR, Ottini L, Fox SB.
    • Histopathology. 2016 Jan;68(1):110-8. doi: 10.1111/his.12862.
    • How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.
    • Lynce F, Isaacs C.
    • Am Soc Clin Oncol Educ Book. 2016;35:e72-e78. doi: 10.14694/EDBK_160391.
    • UK BRCA mutation testing in patients with ovarian cancer.
    • George A.
    • Br J Cancer. 2015 Dec 15;113(S1):S17-S21. doi: 10.1038/bjc.2015.396.
    • Review
    • Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
    • Biesma HD, Schouten PC, Lacle MM, Sanders J, Brugman W, Kerkhoven R, Mandjes I, van der Groep P, van Diest PJ, Linn SC.
    • Genes Chromosomes Cancer. 2015 Dec;54(12):734-44. doi: 10.1002/gcc.22284. Epub 2015 Sep 10.
    • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
    • Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.
    • N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

    Related:

    Comment / Editorial

    Biology before Anatomy in Early Breast Cancer--Precisely the Point.

    Letter

    A 21-Gene Expression Assay in Breast Cancer.

    Letter

    A 21-Gene Expression Assay in Breast Cancer.

    Letter

    A 21-Gene Expression Assay in Breast Cancer.

    Press: Breast Cancer Gene Test Helps Predict Who Can Skip Chemo (NPR)

    • Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
    • Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD.
    • Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13.
    • Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.
    • Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R.
    • J Oncol Pract. 2015 Nov;11(6):442-9. doi: 10.1200/JOP.2015.004127. Epub 2015 Aug 4.
    • Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.
    • Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, Koudijs MJ, Cuppen E, Voest EE, Bernards R, Nederlof PM, Wesseling J, Rodenhuis S, Wessels LF; Center for Personalized Cancer Treatment.
    • Breast Cancer Res. 2015 Oct 3;17(1):134. doi: 10.1186/s13058-015-0642-8.
    • Immunoprofile from tissue microarrays to stratify familial breast cancer patients.
    • Schirosi L, De Summa S, Tommasi S, Paradiso A, Sambiasi D, Popescu O, Simone G, Mangia A.
    • Oncotarget. 2015 Sep 29;6(29):27865-79. doi: 10.18632/oncotarget.4720.
    • Development of a Comprehensive NGS Workflow for the Analysis of Tumor BRCA1 and BRCA2 Mutations and Large Rearrangements.
    • Dong Z, Dong H, Zhong X, Peng Z, Zhu X, Sun Y, Chen Y, Liu C, Yin X, Zhu G, Zheng H, Gu Y.
    • J Genet Genome Res 2(2):019. 2015 Sep 28.
    • Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
    • Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, Felten SJ, Sinnwell JP, Thompson KJ, Tang X, Vedell PT, Barman P, Sicotte H, Eckel-Passow JE, Northfelt DW, Gray RJ, McLaughlin SA, Moreno-Aspitia A, Ingle JN, Moyer AM, Visscher DW, Jones K, Conners A, McDonough M, Wieben ED, Wang L, Weinshilboum R, Boughey JC, Goetz MP.
    • Breast Cancer Res Treat. 2015 Sep;153(2):435-43. doi: 10.1007/s10549-015-3545-6. Epub 2015 Aug 22.
    • A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    • Dietel M, Jöhrens K, Laffert MV, Hummel M, Bläker H, Pfitzner BM, Lehmann A, Denkert C, Darb-Esfahani S, Lenze D, Heppner FL, Koch A, Sers C, Klauschen F, Anagnostopoulos I.
    • Cancer Gene Ther. 2015 Sep;22(9):417-30. doi: 10.1038/cgt.2015.39. Epub 2015 Sep 11.
    • The importance of proper bioinformatics analysis and clinical interpretation of tumor genomic profiling: a case study of undifferentiated sarcoma and a constitutional pathogenic BRCA2 mutation and an MLH1 variant of uncertain significance.
    • Varga E, Chao EC, Yeager ND.
    • Fam Cancer. 2015 Sep;14(3):481-5. doi: 10.1007/s10689-015-9790-3.
    • Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.
    • Chapman JS, Asthana S, Cade L, Chang MT, Wang Z, Zaloudek CJ, Ueda S, Collisson EA, Taylor BS.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):835-45.
    • Germ-Line, Other Actionable Mutations Reported with Next-Generation Sequencing.
    • [No author given]
    • ASCO Daily News. 2015 ASCO Annual Meeting. 2015 Jun 1.
    • Whole-genome characterization of chemoresistant ovarian cancer.
    • Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.
    • Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410.
    • Breast cancer under age 40: a different approach.
    • Ribnikar D, Ribeiro JM, Pinto D, Sousa B, Pinto AC, Gomes E, Moser EC, Cardoso MJ, Cardoso F.
    • Curr Treat Options Oncol. 2015 Apr;16(4):334. doi: 10.1007/s11864-015-0334-8.
    • Review
    • A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing.
    • Ellison G, Huang S, Carr H, Wallace A, Ahdesmaki M, Bhaskar S, Mills J.
    • BMC Clin Pathol. 2015 Mar 24;15:5. doi: 10.1186/s12907-015-0004-6. eCollection 2015.
    • Therogenetics: transferring GWAS technology to the clinic.
    • Cox DG, Heudel PE, Trédan O, Bachelot T.
    • Mutagenesis. 2015 Mar;30(2):213-5. doi: 10.1093/mutage/geu060.
    • High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients.
    • Kalniete D, Nakazawa-Miklaševiča M, Štrumfa I, Āboliņš A, Irmejs A, Gardovskis J, Miklaševičs E.
    • Hered Cancer Clin Pract. 2015 Feb 8;13(1):7. doi: 10.1186/s13053-015-0028-z. eCollection 2015.
    • Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
    • Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T; kConFab Investigators, Fellowes A, Dobrovic A, Fox SB.
    • Br J Cancer. 2014 Dec 9;111(12):2351-2360. doi: 10.1038/bjc.2014.511.
    • Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    • Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.
    • Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
    • Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
    • De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J, Reis-Filho JS.
    • Mol Oncol. 2014 Feb;8(1):150-8. doi: 10.1016/j.molonc.2013.10.006. Epub 2013 Oct 31.
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • Calls for genetic screening of ovarian cancer patients.
    • Philippa Brice.
    • PHG Foundation. 2013 Sep 18.
    • Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.
    • Martinez-Delgado B, Gallardo M, Tanic M, Yanowsky K, Inglada-Perez L, Barroso A, Rodriguez-Pinilla M, Cañamero M, Blasco MA, Benitez J.
    • Breast Cancer Res Treat. 2013 Sep;141(2):231-42. doi: 10.1007/s10549-013-2696-6. Epub 2013 Sep 15.
    • Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    • Gan A, Green AR, Nolan CC, Martin S, Deen S.
    • Hum Pathol. 2013 Aug;44(8):1638-47. doi: 10.1016/j.humpath.2013.01.015. Epub 2013 Apr 8.
    • Multiplex DNA sensor for BRAF and BRCA detection.
    • Ai X, Ma Q, Su X.
    • Anal Biochem. 2013 Jul 1;438(1):22-8. doi: 10.1016/j.ab.2013.02.029. Epub 2013 Mar 13.
    • Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    • Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG.
    • Breast Cancer Res Treat. 2013 Jul;140(2):375-84. doi: 10.1007/s10549-013-2637-4. Epub 2013 Jul 16.
    • Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    • Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.
    • Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.
    • Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
    • Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M.
    • PLoS One. 2013 May 21;8(5):e64268. doi: 10.1371/journal.pone.0064268. Print 2013.
    • BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
    • Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.
    • Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

    Related:

    Research news: Can BRCA Expression Predict Response to Chemotherapy? (Medscape)

    • Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.
    • Zhang J, Shi Y, Lalonde E, Li L, Cavallone L, Ferenczy A, Gotlieb WH, Foulkes WD, Majewski J.
    • BMC Cancer. 2013 Mar 22;13:146. doi: 10.1186/1471-2407-13-146.
    • Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
    • Muñoz-Repeto I, García MJ, Kamieniak M, Ramón Y Cajal T, Domingo S, Cazorla A, García Donas J, Hernando Polo S, García Sagredo JM, Hernández E, Lacambra C, Saez R, Robles L, Borrego S, Prat J, Palacios J, Benítez J.
    • Histol Histopathol. 2013 Jan;28(1):133-44.
    • PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer.
    • Deb S, Do H, Byrne D, Jene N; kConFab Investigators, Dobrovic A, Fox SB.
    • Breast Cancer Res. 2013;15(4):R69.
    • High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    • Willems-Jones A, Kavanagh L, Clouston D, Bolton D; kConFab Investigators, Fox S, Thorne H.
    • BJU Int. 2012 Dec;110(11 Pt C):E1181-6. doi: 10.1111/j.1464-410X.2012.11519.x. Epub 2012 Oct 4.
    • [Translational research and diagnostics for breast cancer].
    • Kreipe HH.
    • Pathologe. 2012 Nov;33 Suppl 2:282-90. doi: 10.1007/s00292-012-1645-1.
    • Review, [Article in German]
    • A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    • Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB.
    • Oncogene. 2012 Oct 18;31(42):4559-66. doi: 10.1038/onc.2011.539. Epub 2011 Dec 5.

    Related:

    Press: Tiny genetic variation can predict ovarian cancer outcome. (EurekAlert!)

    • BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    • Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.
    • Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.
    • Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
    • Zhang M, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Breast Cancer Res Treat. 2012 Feb;132(1):335-40. doi: 10.1007/s10549-011-1887-2. Epub 2011 Nov 25.